var docs;if (!docs) docs =[]; docs["81"]={"8122":"<p><b>Title</b> Levothyroxine / Sucroferric Oxyhydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only anticipated with oral/enteral levothyroxine use.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sucroferric Oxyhydroxide may decrease the serum concentration of Levothyroxine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of oral/enteral levothyroxine and sucroferric oxyhydroxide in combination. The impact of possible alternative strategies such as dose separation has not been evaluated. No interaction is anticipated with parenteral levothyroxine administration.</p> \n<p><b>Discussion</b> Sucroferric oxyhydroxide U.S. prescribing information recommends avoiding coadministration with levothyroxine, based on in vitro data characterizing a potential interaction between these agents in simulated gastrointestinal fluids in vitro.<sup>1</sup> While no further data or description are available, this interaction likely relates to chemical binding/coordination of levothyroxine to the ferric ion moiety of sucroferric oxyhydroxide to form an insoluble or poorly soluble complex, as has been described with the use of several other metal cations with levothyroxine.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Velphoro (sucroferric oxyhydroxide). Waltham, MA: Fresenius Medical Care North America, 12/2013.</p>\n<p>2. Prescribing information. Synthroid (levothyroxine). North Chicago, Il: Abbott Laboratories, March 2008.</p>\n<p>3. Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. <i>Pharmacol Toxicol</i>. 1999;84(3):107-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10193669\">[PubMed 10193669]</a></p>\n<p>4. Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. <i>Am J Med</i>. 1994;97(4):363-365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7942938\">[PubMed 7942938]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8125":"<p><b>Title</b> Tetracyclines / Sucroferric Oxyhydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only anticipated with oral/enteral use of tetracycline derivatives.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sucroferric Oxyhydroxide may decrease the serum concentration of Tetracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer oral/enteral doxycycline at least 1 h before sucroferric oxyhydroxide. Specific dose separation guidelines for other tetracyclines are not presently available. No interaction is anticipated with parenteral administration of tetracyclines.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Sucroferric oxyhydroxide U.S. prescribing information recommends administration of doxycycline at least 1 h before doses of sucroferric oxyhydroxide, based on in vitro data characterizing a potential interaction between these agents in simulated gastrointestinal fluids in vitro.<sup>1</sup> While no further data or description are available, this interaction likely relates to chemical binding/coordination of doxycycline to the ferric ion moiety of sucroferric oxyhydroxide to form an insoluble or poorly soluble complex. Several studies have characterized a potential for decreased oral absorption of tetracycline derivatives (minocycline, doxycycline, tetracycline) and related changes when coadministered with iron salts.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Velphoro (sucroferric oxyhydroxide). Waltham, MA: Fresenius Medical Care North America, 12/2013.</p>\n<p>2. Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. <i>J Am Acad Dermatol</i>. 1985;12(2 Pt 1):308-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3838321\">[PubMed 3838321]</a></p>\n<p>3. Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K. Interference of iron with the absorption of tetracyclines in man. <i>Br Med J</i>. 1970;4(5734):532-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5483323\">[PubMed 5483323]</a></p>\n<p>4. Neuvonen PJ, Pentikainen PJ, Gothoni G. Inhibition of iron absorption by tetracycline. <i>Br J Clin Pharmacol</i>. 1975;2(1):94-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1234494\">[PubMed 1234494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8126":"<p><b>Title</b> Anticholinergic Agents / Umeclidinium</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Umeclidinium may enhance the anticholinergic effect of Anticholinergic Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of umeclidinium with any other drugs that have anticholinergic properties. If such combinations cannot be avoided, monitor patients closely for evidence of anticholinergic-related toxicities (e.g., urinary retention, constipation, tachycardia, dry mouth, etc.).</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Product labeling for both umeclidinium and umeclidinium with vilanterol caution that concurrent use of any other anticholinergic drugs should be avoided due to the risk for additive/excessive anticholinergic effects.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Incruse Ellipta (umeclidinium) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2014.</p>\n<p>2. Anoro Ellipta (umeclidinium and vilanterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.</p>\n<p>3. Incruse Ellipta (umeclidinium) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8127":"<p><b>Title</b> Vortioxetine / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of Vortioxetine. BuPROPion may increase the serum concentration of Vortioxetine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The vortioxetine dose should be reduced by 50% when used together with the strong CYP2D6 inhibitor bupropion. Following cessation of bupropion, the vortioxetine dose should be returned to the normal level. Monitor patient response to vortioxetine extra closely for the duration of concurrent therapy.</p> \n<p><b>Discussion</b> The vortioxetine AUC and maximum serum concentration (Cmax) were an average of 2.3- and 2.1-fold higher, respectively, when vortioxetine (10 mg/day) was given with the strong CYP2D6 inhibitor bupropion (75 mg twice/day for 3 days, then 150 mg twice/day for 11 days) in a cohort of 30 healthy subjects.<sup>1,2</sup> Of note, there was an increase in the report of adverse effects associated with the use of this combination (89% vs. 63% with any reported AE), with headache, nausea/vomiting, insomnia, and dizziness the most commonly reported adverse effects.<sup>1</sup> However, in a separate cohort designed to assess the effects of vortioxetine on bupropion pharmacokinetics, the addition of vortioxetine to bupropion therapy was not associated with an increase in adverse effects (63% vs. 61%), with headache and nausea/vomiting being the most commonly reported adverse effects.<sup>1</sup> Because of the expected magnitude of this interaction, the vortioxetine prescribing information recommends that the vortioxetine dose should be reduced by 50% when used together with a strong CYP2D6 inhibitor such as bupropion.<sup>2</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP2D6-mediated metabolism of vortioxetine leading to an increase in vortioxetine concentrations. CYP2D6 is the primary enzyme responsible for vortioxetine metabolism, though several other enzymes (CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP3A4) also participate.<sup>2</sup><br><br>Another consideration with this combination is a possible increased risk for serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and the selective serotonin reuptake inhibitor (SSRI) sertraline for 3 weeks prior to the onset of symptoms.<sup>3</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>3</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>4,5</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>6,7,8</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>9</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>10,11,12</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>13,14,15</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>16</sup> which is at least partially responsible for the metabolism of some SSRIs (including vortioxetine). This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of the SSRI, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chen G, Lee R, Hojer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. <i>Clin Drug Investig</i>. 2013;33(10):727-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23975654\">[PubMed 23975654]</a></p>\n<p>2. Prescribing information. Brintellix (vortioxetine). Deerfield, IL: Takeda Pharmaceuticals America, Inc., September 2013.</p>\n<p>3. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>4. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>5. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>6. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>7. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>8. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>9. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>10. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>11. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>12. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>13. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropionand sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>14. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J ClinPsychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>15. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use oflow-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>16. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8128":"<p><b>Title</b> Vilazodone / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of Vilazodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> No specific interactions between bupropion and vilazodone have been reported, but reports with other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>1</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>1</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>2,3</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>4,5,6</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>7</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>8,9,10</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>11,12,13</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>14</sup> which is at least partially responsible for the metabolism of many SSRIs (but only minimally so for vilazodone), and some SSRIs may similarly inhibit the CYP2B6-mediated metabolism of bupropion (though vilazodone's potential to inhibit CYP2B6 is unknown).<sup>15</sup> This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of one or both drugs, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>2. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>3. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>4. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>5. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>6. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>8. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>11. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>12. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>13. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>14. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p>15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. <i>Drug Metab Dispos</i>. 2000;28(10):1176-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10997936\">[PubMed 10997936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8129":"<p><b>Title</b> Citalopram / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of Citalopram. BuPROPion may increase the serum concentration of Citalopram. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Initiate citalopram at the lower end of the normal dose range in patients receiving bupropion, and consider limiting the maximum citalopram adult dose to 20 mg/day during concomitant bupropion treatment.</p> \n<p><b>Discussion</b> In a clinical study summarized in naltrexone/bupropion US prescribing information, coadministration of bupropion (300 mg extended-release tablets daily for 14 days) increased the average maximum concentration and AUC of citalopram (40 mg daily for 14 days) by 30% and 40%, respectively.<sup>1</sup><br><br>Although no specific case reports describing toxic effects of combining citalopram and bupropion have been published, reports with other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had previously been treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>2</sup> After initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam, the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>2</sup> Two other published cases have also described suspected serotonin syndrome in patients treated with a combination of bupropion and an SSRI, although in both cases the patient had been previously stable on the combination and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent rather than the bupropion-SSRI combination specifically.<sup>3,4</sup> Several additional case reports describe patients with suspected serotonin syndrome attributed to bupropion alone or to possible interactions with other medications (with at least some possible involvement of bupropion).<sup>5,6,7</sup><br><br>One commentary strongly argues that at least some of these case reports have come to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>8</sup> Bupropion is probably unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>9,10,11</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>12,13,14</sup> although it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) of interaction between these agents is(are) unclear. Naltrexone/bupropion US product labeling recommends initiating citalopram at the lower end of the normal dosing range in patients receiving naltrexone/bupropion.<sup>1</sup> Since increases in citalopram exposure seen with concomitant use of bupropion are similar to those seen with concomitant use of cimetidine, and citalopram US product labeling recommends limiting maximum citalopram doses to 20 mg/day in patients receiving cimetidine, clinicians may also consider limiting citalopram maximum doses to 20 mg/day during bupropion treatment.<sup>15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Contrave</i> (naltrexone/bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc; September 2014.</p>\n<p>2. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>3. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>4. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>5. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>6. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>7. Falls BA, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2014;55(3):305-309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>8. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>9. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>10. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>11. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>12. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>13. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>14. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>15. <i>Celexa</i> (citalopram) [prescribing information]. St. Louis, MO: Forest Laboratories Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8130":"<p><b>Title</b> Escitalopram / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of Escitalopram. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> No specific interactions between bupropion and escitalopram have been reported, but reports with other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>1</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>1</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>2,3</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>4,5,6</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>7</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>8,9,10</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>11,12,13</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>14</sup> which is at least partially responsible for the metabolism of many SSRIs (but not for escitalopram), and some SSRIs may similarly inhibit the CYP2B6-mediated metabolism of bupropion (though escitalopram only minimally inhibited CYP2B6 in vitro).<sup>15</sup> This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of one or both drugs, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>2. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>3. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>4. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>5. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>6. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>8. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>11. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>12. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>13. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>14. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p>15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. <i>Drug Metab Dispos</i>. 2000;28(10):1176-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10997936\">[PubMed 10997936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8131":"<p><b>Title</b> FluvoxaMINE / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of FluvoxaMINE. BuPROPion may increase the serum concentration of FluvoxaMINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient response to this combination extra closely, monitoring patients particularly closely for evidence of fluvoxamine toxicities.</p> \n<p><b>Discussion</b> No specific interactions between bupropion and fluvoxamine have been reported, but reports with other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>1</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>1</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>2,3</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>4,5,6</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>7</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>8,9,10</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>11,12,13</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>14</sup> which is at least partially responsible for the metabolism of many SSRIs (including fluvoxamine), and some SSRIs may similarly inhibit the CYP2B6-mediated metabolism of bupropion (though the calcuated IC50 for fluvoxamine is several-fold greater than usual serum concentrations making the likelihood for a clinically significant interaction low).<sup>15</sup> This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of one or both drugs, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>2. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>3. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>4. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>5. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>6. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>8. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>11. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>12. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>13. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>14. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p>15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. <i>Drug Metab Dispos</i>. 2000;28(10):1176-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10997936\">[PubMed 10997936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8132":"<p><b>Title</b> PARoxetine / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of PARoxetine. BuPROPion may increase the serum concentration of PARoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient response to this combination extra closely, monitoring patients particularly closely for evidence of paroxetine toxicities.</p> \n<p><b>Discussion</b> No specific interactions between bupropion and paroxetine have been reported, but reports with other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>1</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>1</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>2,3</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>4,5,6</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>7</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>8,9,10</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>11,12,13</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>14</sup> which is at least partially responsible for the metabolism of many SSRIs (including paroxetine), and some SSRIs may similarly inhibit the CYP2B6-mediated metabolism of bupropion (though the calcuated IC50 for paroxetine is several-fold greater than usual serum concentrations making the likelihood for a clinically significant interaction low).<sup>15</sup> This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of one or both drugs, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>2. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>3. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>4. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>5. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>6. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>8. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>11. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>12. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>13. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>14. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p>15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. <i>Drug Metab Dispos</i>. 2000;28(10):1176-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10997936\">[PubMed 10997936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8133":"<p><b>Title</b> FLUoxetine / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of FLUoxetine. BuPROPion may increase the serum concentration of FLUoxetine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient response to this combination extra closely, monitoring patients particularly closely for evidence of fluoxetine toxicities.</p> \n<p><b>Discussion</b> Reports with fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>1</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>1</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>2,3</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>4,5,6</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>7</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>8,9,10</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>11,12,13</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>14</sup> which is at least partially responsible for the metabolism of many SSRIs (including fluoxetine), and some SSRIs may similarly inhibit the CYP2B6-mediated metabolism of bupropion (though the calcuated IC50 for both fluoxetine and norfluoxetine are several-fold greater than usual serum concentrations making the likelihood for a clinically significant interaction low).<sup>15</sup> This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of one or both drugs, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>2. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>3. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>4. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>5. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>6. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>8. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>11. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>12. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>13. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>14. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p>15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. <i>Drug Metab Dispos</i>. 2000;28(10):1176-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10997936\">[PubMed 10997936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8134":"<p><b>Title</b> Sertraline / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> BuPROPion may enhance the adverse/toxic effect of Sertraline. BuPROPion may increase the serum concentration of Sertraline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Reports with sertraline and other selective serotonin reuptake inhibitors (SSRIs) suggest that concurrent use of these agents with bupropion may increase the risk for serious toxicities such as serotonin syndrome. A case report describes apparent serotonin syndrome in a 62-year-old woman who had been previously treated with bupropion and sertraline for 3 weeks prior to the onset of symptoms.<sup>1</sup> After the initial symptoms were misinterpreted as worsening/unresolved depression, venlafaxine was added, which was followed by a worsening of symptoms. After discontinuation of all antidepressants and the initiation of cyproheptadine and clonazepam the patient's signs and symptoms improved. Considering that signs and symptoms began within weeks of combined bupropion and sertraline, the authors attributed the apparent serotonin syndrome to an interaction between these antidepressants.<sup>1</sup> Other published cases have also described suspected serotonin syndrome in patients who were being treated with a combination of bupropion and a SSRI, though in both cases the patient had been previously stable on the combination, and the suspected serotonin syndrome was attributed to the addition of another serotonergic agent and not directly to any interaction between bupropion and the SSRI.<sup>2,3</sup> Several more case reports describe patients with suspected serotonin syndrome that was attributed to bupropion alone or to possible interactions between other medications (with at least some possible involvement of bupropion).<sup>4,5,6</sup><br><br>Of note, at least one commentary strongly argues that at least some of these case reports are coming to incorrect conclusions regarding the involvement of bupropion in any suspected serotonin syndrome, stating that substantial data show that bupropion is highly unlikely to cause such a serotonergic reaction.<sup>7</sup> Bupropion is somewhat unique among antidepressants in that its effects do not seem to involve serotonin-related activities, instead being largely dopamine-based in nature.<sup>8,9,10</sup><br><br>Other reactions, including panic, spontaneous orgasm, and delirium have also been reported with combinations of bupropion and individual SSRIs in other published case reports,<sup>11,12,13</sup> though it is not clear whether these represent true interactions or simply effects attributable to one of the drugs and/or to the patient's underlying condition.<br><br>The mechanism(s) for any possible interaction is(are) unclear. Based on the information presented in these cases together with other available data concerning bupropion's actions, it seems unlikely that it would directly cause any enhanced serotonergic activity that could account for observed serotonin syndrome-like presentations. However, bupropion is a strong inhibitor of CYP2D6,<sup>14</sup> which is at least partially responsible for the metabolism of many SSRIs (including sertraline, but only to a limited degree), and some SSRIs may similarly inhibit the CYP2B6-mediated metabolism of bupropion (though the calcuated IC50 for both sertraline and desmethylsertraline are several-fold greater than usual serum concentrations making the likelihood for a clinically significant interaction low).<sup>15</sup> This suggests that some bupropion-SSRI combinations may be associated with increased concentrations of one or both drugs, and increased SSRI concentrations may increase the risk for serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Munhoz RP. Serotonin syndrome induced by a combination of bupropion and SSRIs. <i>Clin Neuropharmacol</i>. 2004;27(5):219-222. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15602102\">[PubMed 15602102]</a></p>\n<p>2. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>3. Shahani L. Tramadol precipitating serotonin syndrome in a patient on antidepressants. <i>J Neuropsychiatry Clin Neurosci</i>. 2012;24(4):E52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23224488\">[PubMed 23224488]</a></p>\n<p>4. Szakaly B, Strauss R. Serotonin syndrome in the oral and maxillofacial surgery office: a review of the literature and report of a case. <i>J Oral Maxillofac Surg</i>. 2008;66(9):1949-1952. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18718407\">[PubMed 18718407]</a></p>\n<p>5. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. <i>J Med Toxicol</i>. 2010;6(2):168-171. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20238197\">[PubMed 20238197]</a></p>\n<p>6. A Falls B, Gurrera RJ. Serotonin syndrome in a patient on tramadol, bupropion, trazodone, and oxycodone. <i>Psychosomatics</i>. 2013; Dec 19 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24360532\">[PubMed 24360532]</a></p>\n<p>7. Gillman PK. Bupropion, bayesian logic and serotonin toxicity. <i>J Med Toxicol</i>. 2010;6(2):276-277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20440594\">[PubMed 20440594]</a></p>\n<p>8. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. <i>J Clin Psychiatry</i>. 1995;56(9):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7665537\">[PubMed 7665537]</a></p>\n<p>9. Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. <i>Cell Mol Neurobiol</i>. 1999;19(4):467-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10379421\">[PubMed 10379421]</a></p>\n<p>10. Kugaya A, Seneca NM, Snyder PJ, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. <i>Neuropsychopharmacology</i>. 2003;28(2):413-420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12589396\">[PubMed 12589396]</a></p>\n<p>11. Grimes JB, Labbate LA. Spontaneous orgasm with the combined use of bupropion and sertraline. <i>Biol Psychiatry</i>. 1996;40(11):1184-1185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8931924\">[PubMed 8931924]</a></p>\n<p>12. Young SJ. Panic associated with combining fluoxetine and bupropion. <i>J Clin Psychiatry</i>. 1996;57(4):177-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8601558\">[PubMed 8601558]</a></p>\n<p>13. Chan CH, Liu HC, Huang MC. Delirium associated with concomitant use of low-dose bupropion sustained release and fluoxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):677-679. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110836\">[PubMed 17110836]</a></p>\n<p>14. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. <i>Ther Drug Monit</i>. 2002;24(3):436-437. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021638\">[PubMed 12021638]</a></p>\n<p>15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. <i>Drug Metab Dispos</i>. 2000;28(10):1176-1183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10997936\">[PubMed 10997936]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8135":"<p><b>Title</b> MetFORMIN / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of MetFORMIN. This includes both a risk for hypoglycemia and for lactic acidosis. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patient response to metformin extra closely if patients are using these drugs concurrently, particularly if patients have other risk factors for hypoglycemia or lactic acidosis. The degree to which ACE inhibitors contribute to an increased risk is unclear, but closer monitoring is likely prudent when possible.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> A published case report described a patient who experienced a severe hypoglycemic episode that was attributed to a possible interaction between metformin and an angiotensin-converting enzyme (ACE) inhibitor.<sup>1</sup> Other case reports similarly describe patients with hypoglycemic episodes attributed to possible interactions between an ACE inhibitor and combination metformin/sulfonylurea, between an ACE inhibitor and a sulfonylurea, and between an ACE inhibitor and insulin.<sup>2,3,4</sup><br><br>Concurrent use of an ACE inhibitor was associated with an increased odds of hospitalization for hypoglycemia (OR=3.2) in a small case-control study that included 64 cases (patients with insulin- or oral antidiabetic medication-treated diabetes who were admitted to the hospital for hypoglycemia) and 440 matched controls.<sup>5</sup> In contrast, concurrent use of ACE inhibitors was not associated with hypoglycemia in a larger case-control study of 404 cases (patients with diabetes hospitalized due to hypoglycemia) and 1375 matched controls.<sup>6</sup> However, use of the specific ACE inhibitor enalapril was associated with hypoglycemia (OR=2.4), despite the lack of an association with the broader class of ACE inhibitors.<br><br>The specific mechanism or mechanisms responsible for this possible interaction is uncertain. While several studies have concluded that ACE inhibitors may improve insulin sensitivity,<sup>7,8,9</sup> others have reported no change in insulin sensitivity with ACE inhibitor therapy.<sup>10,11</sup><br><br>An additional consideration with concurrent use of metformin and ACE inhibitors is the potential for an increased risk of lactic acidosis. Several case reports have described patients who developed lactic acidosis during therapy with both metformin and an ACE inhibitor,<sup>12,13,14,15</sup> though other contributing factors may have been of greater significance in many of these cases. Whether this reported interaction is largely the result of ACE inhibitor-associated decreases in renal function leading to greater metformin concentrations or whether other ACE inhibitor-associated effects increase the risk for lactic acidosis is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zitzmann S, Reimann IR, Schmechel H. Severe hypoglycemia in an elderly patient treated with metformin. <i>Int J Clin Pharmacol Ther</i>. 2002;40(3):108-110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11911598\">[PubMed 11911598]</a></p>\n<p>2. Rett K, Wicklmayr M, Dietze GJ. Hypoglycemia in hypertensive diabetic patients treated with sulfonylureas, biguanides, and captopril. <i>N Engl J Med</i>. 1988;319(24):1609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3059189\">[PubMed 3059189]</a></p>\n<p>3. Arauz-Pacheco C, Ramirez LC, Rios JM, Raskin P. Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin-dependent diabetes receiving sulfonylurea therapy. <i>Am J Med</i>. 1990;89(6):811-813. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2123605\">[PubMed 2123605]</a></p>\n<p>4. Sakaguchi H, Maeda S, Fukunaga Y, Inoue D, Koshiyama H. Hypoglycemia associated with the administration of angiotensin-converting enzyme inhibitor in a patient with diabetes mellitus. <i>Intern Med</i>. 1997;36(1):77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9058108\">[PubMed 9058108]</a></p>\n<p>5. Morris AD, Boyle DI, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. <i>Diabetes Care</i>. 1997;20(9):1363-1367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9283780\">[PubMed 9283780]</a></p>\n<p>6. Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. <i>Clin Ther</i>. 1999;21(8):1387-1400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10485510\">[PubMed 10485510]</a></p>\n<p>7. Rave K, Flesch S, Kuhn-Velten WN, Hompesch BC, Heinemann L, Heise T. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. <i>Diabetes Metab Res Rev</i>. 2005;21(5):459-464. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15915547\">[PubMed 15915547]</a></p>\n<p>8. Tezcan H, Yavuz D, Toprak A, et al. Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients. <i>J Renin Angiotensin Aldosterone Syst</i>. 2003;4(2):119-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12806595\">[PubMed 12806595]</a></p>\n<p>9. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. <i>Br J Clin Pharmacol</i>. 1998;46(5):467-471. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9833600\">[PubMed 9833600]</a></p>\n<p>10. Goossens GH, Blaak EE, Schiffers PM, Saris WH, van Baak MA. Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects. <i>Diabetologia</i>. 2006;49(12):3009-3016. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17019594\">[PubMed 17019594]</a></p>\n<p>11. Heise T, Heinemann L, Kristahn K, Berger M, Sawicki PT. Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. <i>Horm Metab Res</i>. 1999;31(7):418-423. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10450833\">[PubMed 10450833]</a></p>\n<p>12. Plumb B, Parker A, Wong P. Feeling blue with metformin-associated lactic acidosis. <i>BMJ Case Rep</i>. 2013;2013. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23456165\">[PubMed 23456165]</a></p>\n<p>13. Galea M, Jelacin N, Bramham K, White I. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. <i>Br J Anaesth</i>. 2007;98(2):213-215. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17251212\">[PubMed 17251212]</a></p>\n<p>14. al-Jebawi AF, Lassman MN, Abourizk NN. Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. <i>Diabetes Care</i>. 1998;21(8):1364-1365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9702449\">[PubMed 9702449]</a></p>\n<p>15. Franzetti I, Paolo D, Marco G, Emanuela M, Elisabetta Z, Renato U. Possible synergistic effect of metformin and enalapril on the development of hyperkaliemic lactic acidosis. <i>Diabetes Res Clin Pract</i>. 1997;38(3):173-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9483383\">[PubMed 9483383]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8136":"<p><b>Title</b> Ticagrelor / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Ticagrelor. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients using this combination should be monitored extra closely for signs of excessive response to ticagrelor, particularly following cyclosporine initiation and/or dose increase.</p> \n<p><b>Discussion</b> The ticagrelor AUC and maximum serum concentration (Cmax) were increased by an average of 2.8- and 2.3-fold, respectively, in a study of 26 healthy volunteers who received single doses of both cyclosporine (600 mg) and ticagrelor (180 mg).<sup>1</sup> The AUC of the ticagrelor active metabolite (AR-C124910XX) was an average of 33% higher, while the AR-C124910XX Cmax was an average of 15% lower, with concurrent cyclosporine.<br><br>Concentrations of cyclosporine were not significantly altered by concurrent ticagrelor.<sup>1</sup><br><br>The exact mechanism for this interaction is uncertain, but cyclosporine inhibition of p-glycoprotein and/or CYP3A are likely to be at least partially responsible.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Teng R, Kujacic M, Hsia J. Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. <i>Clin Drug Investig</i>. 2014; May 27. (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24861133\">[PubMed 24861133]</a></p>\n<p>2. <i>Brilinta</i> (ticagrelor) [prescribing information]. Wilmington, DE: AstraZeneca LP; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8137":"<p><b>Title</b> Anthracyclines / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyclophosphamide may enhance the cardiotoxic effect of Anthracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cardiac function particularly closely when anthracyclines and cyclophosphamide are used in combination. Cardiotoxic effects of these agents may be additive or synergistic. Administration of cyclophosphamide by infusion or twice daily, or using liposomal anthracycline formulations may reduce risk.</p>\n<div>\n <p><b>Anthracyclines Interacting Members</b> DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, IDArubicin</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for systemic anthracyclines warns that cardiotoxic effects of the drugs may be enhanced by concomitant use of other cardiotoxic drugs, with some (doxorubicin, daunorubicin) specifically citing cyclophosphamide as a potentially interacting agent.<sup>1,2,3,4</sup> Cardiotoxic effects of the independent drugs have been described widely, and at least some data suggest that a lower cyclophosphamide dose is needed to reduce ejection fraction in patients treated concomitantly with anthracyclines.<sup>5</sup> While these drugs are frequently prescribed in combination, particularly close monitoring may be warranted for adverse cardiac effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, October 2013.</p>\n<p>2. Prescribing information.Daunorubicin. Bedford, OH: Bedford Laboratories, June 2013.</p>\n<p>3. Prescribing information. Idamycin (idarubicin). New York, NY: Pfizer Inc, January 2006.</p>\n<p>4. Prescribing information. Ellence (epirubicin). New York, NY: Pfizer Inc, February 2013.</p>\n<p>5. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. <i>J Clin Oncol</i>. 2005;23(30):7685-7696. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16234530\">[PubMed 16234530]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8138":"<p><b>Title</b> DOXOrubicin (Conventional) / Dexrazoxane</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Recommendations in this monograph apply only to the use of dexrazoxane for cardioprotection.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexrazoxane may diminish the therapeutic effect of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Do not administer dexrazoxane for cardioprotection at the time of doxorubicin initiation. This recommendation does not apply to the use of dexrazoxane for other indications (e.g., extravasation), or to the use of dexrazoxane later in doxorubicin treatment.</p> \n<p><b>Discussion</b> In a clinical study of women with metastatic breast cancer receiving combination chemotherapy (fluorouracil, doxorubicin, and cyclophosphamide), coadministration of dexrazoxane with doxorubicin (dexrazoxane:doxorubicin dose ratio 10:1) was associated with a lower objective tumor response rate (48% vs. 63%), without any difference in survival, compared to doxorubicin alone.<sup>1,2,3</sup> Doxorubicin U.S. prescribing information specifically states that dexrazoxane should not be used for cardioprotection at the initiation of doxorubicin treatment.<sup>3</sup> Dexrazoxane is not indicated for cardioprotection until a cumulative doxorubicin dose of 300 mg/m2 has been reached.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. <i>J Clin Oncol</i>. 1997;15(4):1318-1332. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9193323\">[PubMed 9193323]</a></p>\n<p>2. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>3. Prescribing information. Zinecard (dexrazoxane). New York, NY: Pfizer Inc, 7/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8139":"<p><b>Title</b> Factor VIIa (Recombinant) / Factor XIII A-Subunit (Recombinant)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Factor XIII A-Subunit (Recombinant) may enhance the thrombogenic effect of Factor VIIa (Recombinant). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients who receive factor XIII A-subunit and factor VIIa in combination closely for evidence of thrombosis.</p> \n<p><b>Discussion</b> In a preclinical study summarized in factor XIII A-subunit U.S. prescribing information, administration of high doses of recombinant factor VIIa and factor XIII A-subunit in combination (at doses 11 and 17 times expected human doses, respectively) caused a thrombosis related death in 1 of 12 treated monkeys.<sup>1</sup> Additional risk factors for thrombosis in these monkeys included anesthesia induction and the presence of 6 indwelling catheters. Based on this death, prescribing information warns that coadministration of recombinant factor VIIa and factor XIII A-subunit may cause thrombosis. An increase in risk may be possible even at typical doses, based on the independent effects of the agents on coagulation and clot stability.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tretten (coagulation factor XIII A-subunit, recombinant). Plainsboro, NJ: Novo Nordisk Inc., January 2014.</p>\n<p>2. Johansson PI, Jacobsen N, Viuff D, et al. Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers. <i>Br J Haematol</i>. 2008;143(4):559-569. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18950467\">[PubMed 18950467]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8140":"<p><b>Title</b> Treprostinil / Alcohol (Ethyl)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b> (Tablet, extended release): This interaction is only anticipated with treprostinil extended-release tablets.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase the absorption of Treprostinil. Specifically, a more rapid and/or complete absorption of Treprostinil from extended-release tablets is possible. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid administration of treprostinil extended release tablets with alcohol, and advise patients to avoid this combination. Coadministration with alcohol could lead to more rapid and/or complete absorption of treprostinil, and increase the risk of toxicity. No such interaction is expected with other treprostinil formulations.</p> \n<p><b>Discussion</b> U.S. prescribing information for treprostinil extended release tablets recommends that it should not be taken with alcohol, due to the potential for a more rapid release of treprostinil form the tablet.<sup>1</sup> No such interaction is expected with other treprostinil formulations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Orenitram</i> (treprostinil) [Prescribing information]. Research Triangle Park, NC: United Therapeutics Corp., December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8141":"<p><b>Title</b> Carbocisteine / Sulfonylureas</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is specific to only liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a disulfiram-like reaction (i.e., flushing, nausea, etc.) with sulfonylureas in some patients. Although the development of facial flushing is typically not of clinical concern, it may cause embarrassment or anxiety for the uninformed patient. Warn patients of the potential for developing this reaction (especially with chlorpropamide). Monitor for reduced efficacy of tolbutamide in patients also ingesting alcohol. Solid oral dosage forms of carbocisteine products are not expected to share this interaction with sulfonylureas.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Patients receiving chlorpropamide will often manifest facial flushing (warm, tingling, burning sensation) soon after ingestion of alcohol (aka chlorpropamide-alcohol flush).<sup>1,2,3,4</sup> The same has been reported, though rarely, with several other sulfonylureas.<sup>2,5,6</sup> It is a disulfiram-like reaction, possibly via a similar mechanism. The reaction appears to be more of a nuissance than of any significant clinical importance.<br><br>Additionally, tolbutamide clearance appears to be increased by alcohol.<sup>7,8</sup> The half-life is reduced by approximately 33%. Ethanol may increase tolbutamide metabolism. Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>9,10,11,12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnston C, Wiles PG, Pyke DA. Chlorpropamide-alcohol flush: the case in favour. <i>Diabetologia</i>. 1984;26(1):1-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6368296\">[PubMed 6368296]</a></p>\n<p>2. Leslie RD, Pyke DA. Chlorpropamide-alcohol flushing: a dominantly inherited trait associated with diabetes. <i>BMJ</i>. 1978;2(6151):1519-1521. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=728707\">[PubMed 728707]</a></p>\n<p>3. Hillson RM, Hockaday TD. Chlorpropamide-alcohol flush: a critical reappraisal. <i>Diabetologia</i>. 1984;26(1):6-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6706045\">[PubMed 6706045]</a></p>\n<p>4. Groop L, Eriksson CJ, Huupponen R, et al. Roles of chlorpropamide, alcohol and acetaldehyde in determining the chlorpropamide-alcohol flush. <i>Diabetologia</i>. 1984;26(1):34-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6706043\">[PubMed 6706043]</a></p>\n<p>5. Conget JI, Vendrell J, Esmatjes E, et al. Gliclazide alcohol flush. <i>Diabetes Care</i>. 1989;12(1):44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2714170\">[PubMed 2714170]</a></p>\n<p>6. McKendry JB, Gfeller KF. Clinical experience with the oral antidiabetic compound, tolazamide. <i>Can Med Assoc J</i>. 1967;96(9):531-535. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6019353\">[PubMed 6019353]</a></p>\n<p>7. Carulli N, Manenti F, Gallo M, et al. Alcohol-drugs interaction in man: alcohol and tolbutamide. <i>Eur J Clin Invest</i>. 1971;1(6):421-424. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5121732\">[PubMed 5121732]</a></p>\n<p>8. Kater RM, Tobon F, Iber FL. Increased rate of tolbutamide metabolism in alcoholic patients. <i>JAMA</i>. 1969;207(2):363-365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818164\">[PubMed 5818164]</a></p>\n<p>9. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>10. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>11. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>12. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8142":"<p><b>Title</b> Carbocisteine / Disulfiram</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Carbocisteine. Specifically, disulfiram may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combining liquid formulations of carbocisteine with disulfiram when possible. Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a variety of toxicities when combined with disulfiram (i.e., flushing, nausea, etc.) in some patients. Monitor for flushing and changes in blood pressure and/or heart rate if an alcohol-containing carbocisteine is administered to a patient taking disulfiram. Solid oral dosage forms of carbocisteine products are not expected to share this interaction with disulfiram.</p> \n<p><b>Discussion</b> Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose,<sup>1,2,3,4</sup> which when combined with disulfiram can result in an array of symptoms including throbbing in the head and neck, flushing, sweating, nausea, vomiting, chest pain, and breathing difficulties. These effects were first described in 1937 in rubber industry workers handling tetramethylthiuram disulphide.<sup>5</sup> The syndrome was later characterized with disulfiram.<sup>6</sup> Disulfiram inhibits aldehyde dehydrogenase, the enzyme responsible for converting acetaldehyde (the first metabolite of alcohol) into, eventually, water and carbon dioxide. Acetaldehyde accumulation results in the toxic reactions observed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>2. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>3. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>4. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p>5. Williams EE. Effects of alcohol on workers with carbon disulfide. <i>JAMA</i>. 1937;109:1472.</p>\n<p>6. Hald J, Jacobsen E, Larsen V. The sensitizing effects of tetramethylthiuramdisulfide (Antabuse) to ethylalcohol. <i>Acta Pharmacol</i>. 1948;4:285-296.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8143":"<p><b>Title</b> Carbocisteine / CefoTEtan</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CefoTEtan may enhance the adverse/toxic effect of Carbocisteine. Specifically, cefotetan may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a disulfiram-like reaction (i.e., flushing, nausea, etc.) with cefotetan in some patients. Monitor for flushing and changes in blood pressure and/or heart rate if an alcohol-containing product is administered to patients receiving cefotetan. Solid oral dosage forms of carbocisteine products are not expected to share this interaction with cefotetan.</p> \n<p><b>Discussion</b> Flushing occurred in 5 of 8 normal subjects after receiving ethanol (0.5 mg/kg) following the administration of 3 doses of cefotetan (2 g every 12 hours).<sup>1</sup> Other signs and symptoms of disulfiram-like reactions were noted (e.g., changes in heart rate and blood pressure); however, no changes in the pharmacokinetics of alcohol or acetaldehyde were observed. The mechanism of this interaction is unclear. Other cephalosporins containing a methyltetrazolethiol (MTT) sidechain have been reported to cause a similar reaction, whereas the reaction does not appear to occur with cephalosporins lacking this sidechain.<br><br>Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kline SS, Mauro VF, Forney RB Jr, et al. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. <i>Antimicrob Agents Chemother</i>. 1987;31(9):1328-1331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3479045\">[PubMed 3479045]</a></p>\n<p>2. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>3. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>4. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>5. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8144":"<p><b>Title</b> Carbocisteine / MetroNIDAZOLE (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, metronidazole may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of alcohol with metronidazole or within 3 days after stopping metronidazole is a listed contraindication in the metronidazole prescribing information. The specific concern is that a disulfiram-like reaction could result from coadministration of alcohol and metronidazole (although evidence currently stands against the development of a true disulfiram-like reaction). Liquid formulations of carbocisteine-containing products contain alcohol, which may interact with metronidazole in some patients. Solid oral dosage forms of carbocisteine products are not expected to share this interaction with cefotetan.</p> \n<p><b>Discussion</b> Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>1,2,3,4</sup><br><br>Several case reports describe signs and symptoms of a disulfiram-like reaction during coadministration of alcohol and metronidazole.<sup>5,6,7,8,9,10</sup> Reported reactions have ranged from mild cardiovascular effects to death. Randomized, double-blind, placebo-controlled trials, however, have failed to demonstrate the value of metronidazole as an alcohol aversive agent.<sup>11,12,13,14,15,16</sup> The results of these trials suggest that if a reaction does occur, it does so in an unpredictable and relatively mild fashion. The mechanism of a metronidazole-alcohol interaction, if one does occur, is unclear. A disulfiram-like reaction presumes that metronidazole increases acetaldehyde concentrations by inhibiting acetaldehyde dehydrogenase, thereby inhibiting the metabolism of acetaldehyde to acetic acid. A double-blind study involving 12 normal subjects demonstrated no effect of metronidazole on acetaldehyde concentrations.<sup>17</sup> Use of alcohol with metronidazole or within 3 days after stopping metronidazole is a listed contraindication in the metronidazole prescribing information.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>2. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>3. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>4. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p>5. Taylor JAT. Metronidazole - a new agent for combined somatic and psychic therapy for alcoholism: a case study and preliminary report. <i>Bull Los Angeles Neurol Soc</i>. 1964;29:58-62.</p>\n<p>6. Sansoy OM, Vegas L. Evaluation of metronidazole in the treatment of alcoholism. <i>J Indian Med Assoc</i>. 1970;55:29.</p>\n<p>7. De Mattos H. Relationship between alcoholism and the digestive system. <i>Hospital</i>. 1968;74:281.</p>\n<p>8. Edwards DL, Fink PC, Van Dyke PO. Dislufiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole. <i>Clin Pharm</i>. 1986;5(12):999-1000.</p>\n<p>9. Plosker GL. Possible interaction between ethanol and vaginally administered metronidazole. <i>Clin Pharm</i>. 1987;6(3):189,192-193.</p>\n<p>10. Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ethanol interaction. <i>Am J Forensic Med Pathol</i>. 1996;17(4):343-346.</p>\n<p>11. Linton PH, Hain JD. Metronidazole in the treatment of alcoholism. <i>Quarterly J Stud Alcohol</i>. 1967;28(3):544-546.</p>\n<p>12. Egan WP, Goetz R. Effect of metronidazole on drinking by alcoholics. <i>Quarterly J Stud Alcohol</i>. 1968;29(4):899-902.</p>\n<p>13. Penick SB, Carrier RN, Sheldon JB. Metronidazole in the treatment of alcoholism. <i>Am J Psychiatry</i>. 1969;125(8):1063-1066.</p>\n<p>14. Strassman HD, Adams B, Pearson AW. Metronidazole effect on social drinkers. <i>Quarterly J Stud Alcohol</i>. 1970;31(2):394-398.</p>\n<p>15. Platz A, Panepinto WC, Kissin B, et al. Metronidazole and alcoholism. <i>Dis Nerv Syst</i>. 1970;31(9):631-636.</p>\n<p>16. Kaplan R, Blume S, Rosenberg S, et al. Phenytoin, metronidazole and multivitamins in the treatment of alcoholism. <i>Quarterly J Stud Alcohol</i>. 1972;33(1):94-104.</p>\n<p>17. Visapaa JP, Tillonen JS, Kaihovaara PS, et al. Lack of disulfiram-like reaction with metronidazole and ethanol. <i>Ann Pharmacother</i>. 2002;36(6):971-974.</p>\n<p>18. Prescribing information. Flagyl (metronidazole). New York, NY: Pfizer Inc, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8145":"<p><b>Title</b> Dapagliflozin / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Dapagliflozin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers summarized in dapagliflozin U.S. prescribing information, coadministration of rifampin (600 mg daily for 8 days) decreased the AUC of dapagliflozin (10 mg single dose on rifampin day 6) by 22% without affecting its maximum serum concentration.<sup>1,2</sup> Urinary glucose elimination in the first 24 hours following dapagliflozin administration was roughly 10% lower during rifampin coadministration.<br><br>The mechanism of this interaction is unclear. The major known pathway of dapagliflozin metabolism is via UGT1A9 mediated glucuronidation. However, most data from the above study suggest that rifampin may have primarily modified non-UGT1A9 elimination pathways (exposure to the major glucuronide metabolite, and its renal elimination, were both reduced).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Farxiga (dapagliflozin). Princeton, NJ: Bristol-Myers Squibb Company, January 2014.</p>\n<p>2. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. <i>Diabetes Obes Metab</i>. 2013;15(3):280-283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23061428\">[PubMed 23061428]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8146":"<p><b>Title</b> Dapagliflozin / Mefenamic Acid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mefenamic Acid may increase the serum concentration of Dapagliflozin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers summarized in dapagliflozin U.S. prescribing information, coadministration of mefenamic acid (500 mg once, then 250 mg every 6 h for 14 doses) increased the maximum concentration and AUC of dapagliflozin (10 mg single dose with mefenamic acid dose 5) by 13% and 51%, respectively.<sup>1,2</sup> Urinary glucose elimination in the first 24 hours following dapagliflozin administration was roughly 18% higher during mefenamic acid coadministration.<br><br>The suspected primary mechanism of this interaction is mefenamic acid mediated inhibition of UGT1A9 mediated dapagliflozin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Farxiga (dapagliflozin). Princeton, NJ: Bristol-Myers Squibb Company, January 2014.</p>\n<p>2. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. <i>Diabetes Obes Metab</i>. 2013;15(3):280-283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23061428\">[PubMed 23061428]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8147":"<p><b>Title</b> Betahistine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may increase the serum concentration of Betahistine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for an increased risk of systemic betahistine toxicity in patients treated with monoamine oxidase inhibitors.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for betahistine warns that inhibitors of monoamine oxidase may inhibit betahistine metabolism, potentially necessitating betahistine dose modification.<sup>1</sup> No specific human data describing this interaction are available, although one published report suggests that monoamine oxidase is a major determinant of hepatic metabolism of betahistine in rats.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Serc (betahistine). St-Laurent, QC: Abbott Laboratories, Limited, April 2013.</p>\n<p>2. Sternson LA, Tobia AJ, Walsh GM, Sternson AW. The metabolism of betahistine in the rat. <i>Drug Metab Dispos</i>. 1974;2(2):123-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4150992\">[PubMed 4150992]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8148":"<p><b>Title</b> DOXOrubicin (Conventional) / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with CYP3A4 inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to strong CYP3A4 inhibitors in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically increase doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>In one clinical study, intravenous coadministration of the P-gp inhibitor zosquidar at doses of 500 mg or greater increased the AUC of doxorubicin by 15-25% and decreased apparent clearance of its active metabolite doxorubicinol by an estimated 48%.<sup>4,5</sup> The P-gp inhibitor progesterone, administered by continuous intravenous infusion, increased the hematologic toxicity of doxorubicin without affecting systemic exposure to either doxorubicin or doxorubicinol in another study.<sup>6</sup> Cyclosporine, an inhibitor of P-gp and a moderate inhibitor of CYP3A4, increased AUCs of doxorubicin and doxorubicinol by 48% and 443%, respectively, and increased myelotoxicity in a small study of patients with small cell lung cancer.<sup>7</sup> Several other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose requirements with concurrent cyclosporine use.<sup>8,9,10,11</sup> Ketoconazole (a strong CYPA4 inhibitor and P-gp inhibitor) has also been used with doxorubicin in one pilot study, but no pharmacokinetic data or comparisons to doxorubicin alone are available.<sup>12</sup><br><br>Other available data are less clear as to the interaction potential when doxorubicin is used with inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. In one retrospective analysis, 24 patients with non-Hodgkin lymphoma who received “CHOP” chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (saquinavir, indinavir, ritonavir, or nevirapine/ritonavir) had a greater incidence of grade 3-4 anemia (33% vs. 7%) and severe autonomic neurotoxicity (17% vs. 0%) than 80 patients who received similar chemotherapy regimens without protease inhibitors.<sup>13</sup> In a subsequent crossover study of 19 patients with HIV and NHL, however, use of an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (indinavir, saquinavir, or nelfinavir) during CHOP chemotherapy was associated with no difference in doxorubicin maximum concentration or AUC compared to CHOP chemotherapy alone.<sup>14</sup> The potential impact on doxorubicinol exposure was not investigated. Finally, one pharmacogenetic study described a roughly 16% decrease in doxorubicin clearance in individuals carrying alleles associated with lower pregnane X receptor (PXR) associated CYP3A4 and P-gp expression,<sup>15</sup> while a separate pharmacogenetic study found no correlation between doxorubicin pharmacokinetic variants and variants in genes coding for PXR and 2 functionally related nuclear receptors (constitutive androstane receptor and hepatocyte nuclear factor 4 alpha).<sup>16</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p>4. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. <i>Clin Cancer Res</i>. 2004;10(10):3265-3272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15161679\">[PubMed 15161679]</a></p>\n<p>5. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). <i>Cancer Chemother Pharmacol</i>. 2003;51(2):107-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12647011\">[PubMed 12647011]</a></p>\n<p>6. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. <i>J Clin Oncol</i>. 1993;11(12):2417-2426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8246031\">[PubMed 8246031]</a></p>\n<p>7. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. <i>Cancer</i>. 1994;74(3):834-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>8. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. <i>Cancer Res</i>. 1993;53(20):4837-4842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>9. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. <i>Eur J Haematol</i>. 1994;52(5):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>10. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. <i>J Clin Oncol</i>. 1994;12(4):835-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>11. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). <i>Br J Haematol</i>. 2001;115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>12. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <i>J Clin Oncol</i>. 1994;12(4):683-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7512126\">[PubMed 7512126]</a></p>\n<p>13. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>14. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p>15. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clin Cancer Res</i>. 2008;14(21):7116-7126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981011\">[PubMed 18981011]</a></p>\n<p>16. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics J</i>. 2008;8(2):139-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17876342\">[PubMed 17876342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8149":"<p><b>Title</b> DOXOrubicin (Conventional) / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with CYP2D6 inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil<br><b>Exception</b> Grapefruit Juice</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically increase doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>In one clinical study, intravenous coadministration of the P-gp inhibitor zosquidar at doses of 500 mg or greater increased the AUC of doxorubicin by 15-25% and decreased apparent clearance of its active metabolite doxorubicinol by an estimated 48%.<sup>4,5</sup> The P-gp inhibitor progesterone, administered by continuous intravenous infusion, increased the hematologic toxicity of doxorubicin without affecting systemic exposure to either doxorubicin or doxorubicinol in another study.<sup>6</sup> Cyclosporine, an inhibitor of P-gp and a moderate inhibitor of CYP3A4, increased AUCs of doxorubicin and doxorubicinol by 48% and 443%, respectively, and increased myelotoxicity in a small study of patients with small cell lung cancer.<sup>7</sup> Several other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose requirements with concurrent cyclosporine use.<sup>8,9,10,11</sup> Ketoconazole (a strong CYPA4 inhibitor and P-gp inhibitor) has also been used with doxorubicin in one pilot study, but no pharmacokinetic data or comparisons to doxorubicin alone are available.<sup>12</sup><br><br>Other available data are less clear as to the interaction potential when doxorubicin is used with inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. In one retrospective analysis, 24 patients with non-Hodgkin lymphoma who received “CHOP” chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (saquinavir, indinavir, ritonavir, or nevirapine/ritonavir) had a greater incidence of grade 3-4 anemia (33% vs. 7%) and severe autonomic neurotoxicity (17% vs. 0%) than 80 patients who received similar chemotherapy regimens without protease inhibitors.<sup>13</sup> In a subsequent crossover study of 19 patients with HIV and NHL, however, use of an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (indinavir, saquinavir, or nelfinavir) during CHOP chemotherapy was associated with no difference in doxorubicin maximum concentration or AUC compared to CHOP chemotherapy alone.<sup>14</sup> The potential impact on doxorubicinol exposure was not investigated. Finally, one pharmacogenetic study described a roughly 16% decrease in doxorubicin clearance in individuals carrying alleles associated with lower pregnane X receptor (PXR) associated CYP3A4 and P-gp expression,<sup>15</sup> while a separate pharmacogenetic study found no correlation between doxorubicin pharmacokinetic variants and variants in genes coding for PXR and 2 functionally related nuclear receptors (constitutive androstane receptor and hepatocyte nuclear factor 4 alpha).<sup>16</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p>4. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. <i>Clin Cancer Res</i>. 2004;10(10):3265-3272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15161679\">[PubMed 15161679]</a></p>\n<p>5. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). <i>Cancer Chemother Pharmacol</i>. 2003;51(2):107-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12647011\">[PubMed 12647011]</a></p>\n<p>6. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. <i>J Clin Oncol</i>. 1993;11(12):2417-2426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8246031\">[PubMed 8246031]</a></p>\n<p>7. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. <i>Cancer</i>. 1994;74(3):834-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>8. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. <i>Cancer Res</i>. 1993;53(20):4837-4842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>9. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. <i>Eur J Haematol</i>. 1994;52(5):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>10. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. <i>J Clin Oncol</i>. 1994;12(4):835-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>11. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). <i>Br J Haematol</i>. 2001;115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>12. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <i>J Clin Oncol</i>. 1994;12(4):683-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7512126\">[PubMed 7512126]</a></p>\n<p>13. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>14. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p>15. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clin Cancer Res</i>. 2008;14(21):7116-7126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981011\">[PubMed 18981011]</a></p>\n<p>16. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics J</i>. 2008;8(2):139-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17876342\">[PubMed 17876342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8150":"<p><b>Title</b> DOXOrubicin (Conventional) / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with CYP3A4 inducers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to strong CYP3A4 inducers in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for altered doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically alter doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8151":"<p><b>Title</b> DOXOrubicin (Conventional) / P-glycoprotein/ABCB1 Inducers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with P-glycoprotein inducers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to P-glycoprotein inducers in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin, St John's Wort</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically alter doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these transporters/enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8152":"<p><b>Title</b> DOXOrubicin (Conventional) / CYP2D6 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with CYP2D6 inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to moderate CYP2D6 inhibitors in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically increase doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>In one clinical study, intravenous coadministration of the P-gp inhibitor zosquidar at doses of 500 mg or greater increased the AUC of doxorubicin by 15-25% and decreased apparent clearance of its active metabolite doxorubicinol by an estimated 48%.<sup>4,5</sup> The P-gp inhibitor progesterone, administered by continuous intravenous infusion, increased the hematologic toxicity of doxorubicin without affecting systemic exposure to either doxorubicin or doxorubicinol in another study.<sup>6</sup> Cyclosporine, an inhibitor of P-gp and a moderate inhibitor of CYP3A4, increased AUCs of doxorubicin and doxorubicinol by 48% and 443%, respectively, and increased myelotoxicity in a small study of patients with small cell lung cancer.<sup>7</sup> Several other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose requirements with concurrent cyclosporine use.<sup>8,9,10,11</sup> Ketoconazole (a strong CYPA4 inhibitor and P-gp inhibitor) has also been used with doxorubicin in one pilot study, but no pharmacokinetic data or comparisons to doxorubicin alone are available.<sup>12</sup><br><br>Other available data are less clear as to the interaction potential when doxorubicin is used with inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. In one retrospective analysis, 24 patients with non-Hodgkin lymphoma who received “CHOP” chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (saquinavir, indinavir, ritonavir, or nevirapine/ritonavir) had a greater incidence of grade 3-4 anemia (33% vs. 7%) and severe autonomic neurotoxicity (17% vs. 0%) than 80 patients who received similar chemotherapy regimens without protease inhibitors.<sup>13</sup> In a subsequent crossover study of 19 patients with HIV and NHL, however, use of an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (indinavir, saquinavir, or nelfinavir) during CHOP chemotherapy was associated with no difference in doxorubicin maximum concentration or AUC compared to CHOP chemotherapy alone.<sup>14</sup> The potential impact on doxorubicinol exposure was not investigated. Finally, one pharmacogenetic study described a roughly 16% decrease in doxorubicin clearance in individuals carrying alleles associated with lower pregnane X receptor (PXR) associated CYP3A4 and P-gp expression,<sup>15</sup> while a separate pharmacogenetic study found no correlation between doxorubicin pharmacokinetic variants and variants in genes coding for PXR and 2 functionally related nuclear receptors (constitutive androstane receptor and hepatocyte nuclear factor 4 alpha).<sup>16</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p>4. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. <i>Clin Cancer Res</i>. 2004;10(10):3265-3272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15161679\">[PubMed 15161679]</a></p>\n<p>5. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). <i>Cancer Chemother Pharmacol</i>. 2003;51(2):107-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12647011\">[PubMed 12647011]</a></p>\n<p>6. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. <i>J Clin Oncol</i>. 1993;11(12):2417-2426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8246031\">[PubMed 8246031]</a></p>\n<p>7. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. <i>Cancer</i>. 1994;74(3):834-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>8. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. <i>Cancer Res</i>. 1993;53(20):4837-4842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>9. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. <i>Eur J Haematol</i>. 1994;52(5):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>10. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. <i>J Clin Oncol</i>. 1994;12(4):835-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>11. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). <i>Br J Haematol</i>. 2001;115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>12. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <i>J Clin Oncol</i>. 1994;12(4):683-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7512126\">[PubMed 7512126]</a></p>\n<p>13. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>14. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p>15. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clin Cancer Res</i>. 2008;14(21):7116-7126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981011\">[PubMed 18981011]</a></p>\n<p>16. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics J</i>. 2008;8(2):139-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17876342\">[PubMed 17876342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8153":"<p><b>Title</b> DOXOrubicin (Conventional) / CYP2D6 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with CYP2D6 inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to strong CYP2D6 inhibitors in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically increase doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>In one clinical study, intravenous coadministration of the P-gp inhibitor zosquidar at doses of 500 mg or greater increased the AUC of doxorubicin by 15-25% and decreased apparent clearance of its active metabolite doxorubicinol by an estimated 48%.<sup>4,5</sup> The P-gp inhibitor progesterone, administered by continuous intravenous infusion, increased the hematologic toxicity of doxorubicin without affecting systemic exposure to either doxorubicin or doxorubicinol in another study.<sup>6</sup> Cyclosporine, an inhibitor of P-gp and a moderate inhibitor of CYP3A4, increased AUCs of doxorubicin and doxorubicinol by 48% and 443%, respectively, and increased myelotoxicity in a small study of patients with small cell lung cancer.<sup>7</sup> Several other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose requirements with concurrent cyclosporine use.<sup>8,9,10,11</sup> Ketoconazole (a strong CYPA4 inhibitor and P-gp inhibitor) has also been used with doxorubicin in one pilot study, but no pharmacokinetic data or comparisons to doxorubicin alone are available.<sup>12</sup><br><br>Other available data are less clear as to the interaction potential when doxorubicin is used with inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. In one retrospective analysis, 24 patients with non-Hodgkin lymphoma who received “CHOP” chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (saquinavir, indinavir, ritonavir, or nevirapine/ritonavir) had a greater incidence of grade 3-4 anemia (33% vs. 7%) and severe autonomic neurotoxicity (17% vs. 0%) than 80 patients who received similar chemotherapy regimens without protease inhibitors.<sup>13</sup> In a subsequent crossover study of 19 patients with HIV and NHL, however, use of an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (indinavir, saquinavir, or nelfinavir) during CHOP chemotherapy was associated with no difference in doxorubicin maximum concentration or AUC compared to CHOP chemotherapy alone.<sup>14</sup> The potential impact on doxorubicinol exposure was not investigated. Finally, one pharmacogenetic study described a roughly 16% decrease in doxorubicin clearance in individuals carrying alleles associated with lower pregnane X receptor (PXR) associated CYP3A4 and P-gp expression,<sup>15</sup> while a separate pharmacogenetic study found no correlation between doxorubicin pharmacokinetic variants and variants in genes coding for PXR and 2 functionally related nuclear receptors (constitutive androstane receptor and hepatocyte nuclear factor 4 alpha).<sup>16</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p>4. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. <i>Clin Cancer Res</i>. 2004;10(10):3265-3272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15161679\">[PubMed 15161679]</a></p>\n<p>5. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). <i>Cancer Chemother Pharmacol</i>. 2003;51(2):107-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12647011\">[PubMed 12647011]</a></p>\n<p>6. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. <i>J Clin Oncol</i>. 1993;11(12):2417-2426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8246031\">[PubMed 8246031]</a></p>\n<p>7. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. <i>Cancer</i>. 1994;74(3):834-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>8. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. <i>Cancer Res</i>. 1993;53(20):4837-4842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>9. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. <i>Eur J Haematol</i>. 1994;52(5):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>10. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. <i>J Clin Oncol</i>. 1994;12(4):835-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>11. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). <i>Br J Haematol</i>. 2001;115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>12. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <i>J Clin Oncol</i>. 1994;12(4):683-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7512126\">[PubMed 7512126]</a></p>\n<p>13. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>14. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p>15. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clin Cancer Res</i>. 2008;14(21):7116-7126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981011\">[PubMed 18981011]</a></p>\n<p>16. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics J</i>. 2008;8(2):139-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17876342\">[PubMed 17876342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8154":"<p><b>Title</b> DOXOrubicin (Conventional) / P-glycoprotein/ABCB1 Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: U.S. labeling for doxorubicin HCl marketed by Pfizer Inc. recommends avoiding its combination with P-glycoprotein inducers.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for doxorubicin, marketed by Pfizer Inc., warns that its use in combination with inhibitors or inducers of CYP3A4, CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from Bedford Laboratories, in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically increase doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>In one clinical study, intravenous coadministration of the P-gp inhibitor zosquidar at doses of 500 mg or greater increased the AUC of doxorubicin by 15-25% and decreased apparent clearance of its active metabolite doxorubicinol by an estimated 48%.<sup>4,5</sup> The P-gp inhibitor progesterone, administered by continuous intravenous infusion, increased the hematologic toxicity of doxorubicin without affecting systemic exposure to either doxorubicin or doxorubicinol in another study.<sup>6</sup> Cyclosporine, an inhibitor of P-gp and a moderate inhibitor of CYP3A4, increased AUCs of doxorubicin and doxorubicinol by 48% and 443%, respectively, and increased myelotoxicity in a small study of patients with small cell lung cancer.<sup>7</sup> Several other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose requirements with concurrent cyclosporine use.<sup>8,9,10,11</sup> Ketoconazole (a strong CYPA4 inhibitor and P-gp inhibitor) has also been used with doxorubicin in one pilot study, but no pharmacokinetic data or comparisons to doxorubicin alone are available.<sup>12</sup><br><br>Other available data are less clear as to the interaction potential when doxorubicin is used with inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. In one retrospective analysis, 24 patients with non-Hodgkin lymphoma who received “CHOP” chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (saquinavir, indinavir, ritonavir, or nevirapine/ritonavir) had a greater incidence of grade 3-4 anemia (33% vs. 7%) and severe autonomic neurotoxicity (17% vs. 0%) than 80 patients who received similar chemotherapy regimens without protease inhibitors.<sup>13</sup> In a subsequent crossover study of 19 patients with HIV and NHL, however, use of an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (indinavir, saquinavir, or nelfinavir) during CHOP chemotherapy was associated with no difference in doxorubicin maximum concentration or AUC compared to CHOP chemotherapy alone.<sup>14</sup> The potential impact on doxorubicinol exposure was not investigated. Finally, one pharmacogenetic study described a roughly 16% decrease in doxorubicin clearance in individuals carrying alleles associated with lower pregnane X receptor (PXR) associated CYP3A4 and P-gp expression,<sup>15</sup> while a separate pharmacogenetic study found no correlation between doxorubicin pharmacokinetic variants and variants in genes coding for PXR and 2 functionally related nuclear receptors (constitutive androstane receptor and hepatocyte nuclear factor 4 alpha).<sup>16</sup><br><br>Overall, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities based on published data. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p>2. Prescribing information. Adriamycin (doxorubicin). Bedford, OH: Bedford Laboratories, 7/2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p>4. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. <i>Clin Cancer Res</i>. 2004;10(10):3265-3272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15161679\">[PubMed 15161679]</a></p>\n<p>5. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). <i>Cancer Chemother Pharmacol</i>. 2003;51(2):107-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12647011\">[PubMed 12647011]</a></p>\n<p>6. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. <i>J Clin Oncol</i>. 1993;11(12):2417-2426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8246031\">[PubMed 8246031]</a></p>\n<p>7. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. <i>Cancer</i>. 1994;74(3):834-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>8. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. <i>Cancer Res</i>. 1993;53(20):4837-4842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>9. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. <i>Eur J Haematol</i>. 1994;52(5):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>10. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. <i>J Clin Oncol</i>. 1994;12(4):835-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>11. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). <i>Br J Haematol</i>. 2001;115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>12. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <i>J Clin Oncol</i>. 1994;12(4):683-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7512126\">[PubMed 7512126]</a></p>\n<p>13. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>14. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p>15. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clin Cancer Res</i>. 2008;14(21):7116-7126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981011\">[PubMed 18981011]</a></p>\n<p>16. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics J</i>. 2008;8(2):139-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17876342\">[PubMed 17876342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8155":"<p><b>Title</b> Mercaptopurine / DOXOrubicin (Conventional)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DOXOrubicin (Conventional) may enhance the hepatotoxic effect of Mercaptopurine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor particularly closely for clinical and laboratory evidence of hepatotoxicity (e.g. elevated transaminase concentrations, elevated bilirubin, jaundice) in patients receiving doxorubicin and mercaptopurine in combination.</p> \n<p><b>Discussion</b> In a clinical study of 19 patients with leukemia treated with doxorubicin (50 mg/m2 on day 1 of a 2-3 week cycle) and mercaptopurine (500 mg/m2/day for 5 days of a 2-3 week cycle), alone or in combination with vincristine and prednisone, 11 patients developed severe hepatotoxicity characterized by elevated total serum bilirubin, elevated alkaline phosphatase, and hepatic necrosis.<sup>1,2</sup> The mechanism of this possible interaction is unknown, and additional reports of widespread hepatotoxicity with this combination have not been published despite numerous clinical trials of regimens containing both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Minow RA, Stern MH, Casey JH, Rodriguez V, Luna MA. Clinico-pathologic correlation of liver damage in patients treated with 6-mercaptopurine and Adriamycin. <i>Cancer</i>. 1976;38(4):1524-1528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1068739\">[PubMed 1068739]</a></p>\n<p>2. Prescribing information. Doxorubicin. New York, NY: Pfizer Inc, 10/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8156":"<p><b>Title</b> Nadolol / Green Tea</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Green Tea may decrease the serum concentration of Nadolol. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Advise patients to minimize green tea consumption during nadolol treatment. The impact of separating nadolol doses from green tea consumption has not been investigated.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, green tea (700 mL/day for 14 days) decreased the maximum concentration and AUC of nadolol (30 mg single oral dose) both by 85%.<sup>1</sup> Nadolol associated reductions in systolic blood pressure (per area under the plasma concentration-effect curve) decreased significantly with green tea coadministration. Non-statistically significant reductions in pulse and diastolic blood pressure effects were also measured.<br><br>The mechanism of this interaction is unclear. Inhibition of active uptake of nadolol (e.g., by OATP1A2 transporters) by green tea components may play a role based on in vitro studies.<sup>1,2</sup> The clinical duration of any such inhibitory effect is unknown, as is the potential impact of separating administration of nadolol and green tea.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mikasa S, Yatabe J, Muller F, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. <i>Clin Pharmacol Ther</i>. 2014 Jan 13. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24419562\">[PubMed 24419562]</a></p>\n<p>2. Roth M, Timmermann BN, Hagenbuch B. Interactions of green tea catechins with organic anion-transporting polypeptides. <i>Drug Metab Dispos</i>. 2011;39(5):920-926. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21278283\">[PubMed 21278283]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8157":"<p><b>Title</b> Vilazodone / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: Vilazodone dose increases should be considered in patients receiving CYP3A4 inducers for greater than 14 days.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg daily), based on clinical response, in patients who receive a strong CYP3A4 inducer for greater than 14 days. Gradually reduce the vilazodone dose back to the original dose over 1 to 2 weeks following discontinuation of the inducer. Monitor vilazodone clinical response closely during concomitant treatment with CYP3A4 inducers regardless of the duration of concomitant treatment.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 23 healthy volunteers, carbamazepine (400 mg daily x 19 days) decreased the vilazodone (40 mg daily x 9 days) AUC and maximum serum concentration 45% and 41%, respectively.<sup>1,2</sup> Vilazodone US prescribing information states that coadministration with strong CYP3A4 inducers may reduce vilazodone systemic exposure and a dose increase up to 2-fold (do not exceed 80 mg daily) should be considered.<sup>2</sup> <br><br>The suspected primary mechanism of this interaction is carbamazepine induction of CYP3A4-mediated vilazodone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boinpally R, Gad N, Gupta S, Periclou A. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. <i>Clin Ther</i>. 2014;36(11):1638-1649. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25236915\">[PubMed 25236915]</a></p>\n<p>2. Viibryd (vilazodone) [prescribing information]. St. Louis, MO: Forest Laboratories Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8158":"<p><b>Title</b> Vitamin K Antagonists / Vaccines</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Vaccines may enhance the anticoagulant effect of Vitamin K Antagonists. However, most available evidence suggests no meaningful change in anticoagulant effect. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Vaccines Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, Anthrax Vaccine Adsorbed, BCG Vaccine (Immunization), Cholera Vaccine, Diphtheria and Tetanus Toxoids, Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), Poliovirus (Inactivated), and Haemophilus influenzae B Conjugate (Adsorbed) Vaccine, Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine, Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B (Recombinant), and Poliovirus (Inactivated) Vaccine, Haemophilus b Conjugate Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine (Recombinant [Adjuvanted]), Hepatitis B Vaccine (Recombinant), Influenza A Virus Vaccine (H5N1), Influenza Virus Vaccine (Inactivated), Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Inactivated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine, Meningococcal Group B Vaccine, Meningococcal Group C-CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (Groups A / C / Y and W-135) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide (Groups C and Y) and Haemophilus b Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Group C Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine (Groups A / C / Y and W-135), Papillomavirus (9-Valent) Vaccine (Human, Recombinant), Papillomavirus (Types 16, 18) Vaccine (Human, Recombinant), Papillomavirus (Types 6, 11, 16, 18) Vaccine (Human, Recombinant), Pneumococcal Conjugate Vaccine (10-Valent), Pneumococcal Conjugate Vaccine (13-Valent), Pneumococcal Conjugate Vaccine (7-Valent), Pneumococcal Polysaccharide Vaccine (23-Valent), Poliovirus Vaccine (Inactivated), Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Q Fever Vaccine, Rabies Vaccine, Rotavirus Vaccine, Smallpox Vaccine Live, Tetanus Toxoid (Adsorbed), Tick-Borne Encephalitis Virus Vaccine (Inactivated), Travelers' Diarrhea and Cholera Vaccine, Typhoid and Hepatitis A Vaccine, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated), Zoster Vaccine (Recombinant)</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> No significant effect on INR values or warfarin weekly doses was found after influenza vaccination administration in patients stable on warfarin therapy in a placebo-controlled, randomized, double-blind crossover study of 104 patients.<sup>1</sup> Multiple prospective and retrospective studies have similarly shown vaccinations to have no effect on anticoagulant effect in long-term stable patients on warfarin.<sup>2,3,4,5,6,7,8,9,10,11</sup> A systematic review of seven studies identified only one study that showed a significant change in mean INR post-vaccination, concluding that, overall, the evidence did not support the existence of a clinically relevant interaction between warfarin and influenza vaccination.<sup>12</sup> With respect to other vitamin K antagonists, one study found no change in acenocoumarol activity in patients that received influenza vaccinations.<sup>13</sup> Though most of these studies have been specific to influenza vaccination, similar results have been found with pneumococcal, tetanus, and hepatitis A vaccinations.<sup>10,11</sup><br><br>In contrast to the several studies concluding that there is no interaction, published case reports describe bleeding and/or increased INR in anticoagulant-treated patients following vaccination.<sup>14,15</sup> An early prospective study also found that the anticoagulant effect was increased after influenza vaccine was administered to patients receiving long-term warfarin therapy.<sup>16</sup> Two other studies, however, reported decreases in anticoagulant effect following vaccination.<sup>6,17</sup> In one, there was no overall effect on anticoagulation, but a decrease in PT values during the first two weeks post-vaccination was noted.<sup>6</sup> In another, a subgroup analysis showed a reduction of anticoagulation effect in patients older than 70 years but no effect in the overall study population.<sup>17</sup><br><br>The preponderance of the available data suggest that vaccination has no clinically meaningful impact on vitamin K antagonist anticoagulation in the vast majority of patients. The mechanism(s) for any potential interaction is(are) uncertain. One proposed mechanism is that the interferon-inducing effect of vaccines leads to inactivation of the cytochrome P450 system, resulting in decreased metabolism of the vitamin K antagonist.<sup>18</sup> In opposition of this as a significant mechanism, a study evaluating warfarin metabolism in healthy volunteers who received the influenza vaccine concluded that vaccination had no significant impact on warfarin metabolism.<sup>14</sup> Another proposed mechanism is that pro-inflammatory cytokines, induced via vaccination, increase thrombin generation and inhibition of fibrin removal.<sup>19</sup> Theoretically, infection and inflammatory response that can be triggered by vaccination could activate pro-inflammatory cytokines, leading to more activated coagulation. However, a study in healthy healthcare workers receiving the 2009 H1N1 influenza vaccination showed no clinically relevant change in coagulation or fibrinolysis parameters within 14 days of vaccination.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Iorio A, Basileo M, Marcucci M, et al. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. <i>Arch Intern Med</i>. 2010;170(7):609-616. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20386004\">[PubMed 20386004]</a></p>\n<p>2. Patriarca PA, Kendal AP, Stricof RL, et al. Influenza vaccination and warfarin or theophylline toxicity in nursing-home residents. <i>N Engl J Med</i>. 1983;308(26):1601-1602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6855841\">[PubMed 6855841]</a></p>\n<p>3. Lipsky BA, Pecoraro RE, Roben NJ, et al. Influenza vaccination and warfarin anticoagulation. <i>Ann Intern Med</i>. 1984;100;(6):835-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6721299\">[PubMed 6721299]</a></p>\n<p>4. Gomolin IH, Chapron DJ, Luhan PA. Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly. <i>J Am Geriatr Soc</i>. 1985;33(4):269-272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3989189\">[PubMed 3989189]</a></p>\n<p>5. Gomolin IH. Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly. <i>CMAJ</i>. 1986;134(1):39-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3719485\">[PubMed 3719485]</a></p>\n<p>6. Bussey HI, Saklad JJ. Effect of influenza vaccine on chronic warfarin therapy. <i>Drug Intell Clin Pharm</i>. 1988;22(3):198-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3366059\">[PubMed 3366059]</a></p>\n<p>7. Arnold WS, Mehta MK, Roberts JS. Influenza vaccine and anticoagulation control in patients receiving warfarin. <i>Br J Clin Pract</i>. 1990;44(4):136-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2372474\">[PubMed 2372474]</a></p>\n<p>8. Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receving long-term warfarin anticoagulation therapy. <i>Arch Intern Med</i>. 1995;155(14):1529-1531. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7605155\">[PubMed 7605155]</a></p>\n<p>9. MacCallum P, Madhani M, Mt-Isa S, et al. Lack of effect of influenza immunization on anticoagulant control in patients on long-term warfarin. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(7):786-789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17111459\">[PubMed 17111459]</a></p>\n<p>10. Jackson ML, Nelson JC, Chen RT, et al. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. <i>Pharmacoepidmiol Drug Saf</i>. 2007;16(7):790-796. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17286320\">[PubMed 17286320]</a></p>\n<p>11. Farrow PR, Nicholson KG. Lack of effect of influenza and pneumococcal vaccines on anticoagulation by warfarin. <i>J Infect</i>. 1984;9(2):157-160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6501905\">[PubMed 6501905]</a></p>\n<p>12. Kuo AM, Brown JN, Clinard V. Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. <i>J Clin Pharm Ther</i>. 2012;37(5):505-509. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22449298\">[PubMed 22449298]</a></p>\n<p>13. Souto JC, Oliver A, Montserrat I, et al. Lack of effect of influenza vaccine on anticoagulation by acenocoumarol. <i>Ann Pharmacother</i>. 1993;27(3):365-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453177\">[PubMed 8453177]</a></p>\n<p>14. Kramer P, Tsuru M, Cooke CE, et al. Effect of influenza vaccine on warfarin anticoagulation. <i>Clin Pharmacol Ther</i>. 1984;35(3):416-418. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6697649\">[PubMed 6697649]</a></p>\n<p>15. Carroll DN, Carroll DG. Fatal intracranial bleed potentially due to a warfarin and influenza vaccine interaction. <i>Ann Pharmacother</i>. 2009;43(4):754-760. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19336651\">[PubMed 19336651]</a></p>\n<p>16. Weibert RT, Lorentz SM, Norcross WA, et al. Effect of influenza vaccine in patients receiving long-term warfarin therapy. <i>Clin Pharm</i>. 1986;5(6):499-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3720216\">[PubMed 3720216]</a></p>\n<p>17. Poli D, Chiarugi L, Capanni M, et al. Need of more frequent International Normalized Ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. <i> Blood Coagul Fibronolysis</i>. 2002;13(4):297-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032394\">[PubMed 12032394]</a></p>\n<p>18. D’Arcy PF. Vaccine-drug interactions. <i>Drug Intell Clin Pharm</i>. 1984;18(9):697-700. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6383754\">[PubMed 6383754]</a></p>\n<p>19. Levi M, Keller TT, van Gorp E, et al. Infection and inflammation and the coagulation system. <i>Cardiovasc Res</i>. 2003;60(1):26-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14522404\">[PubMed 14522404]</a></p>\n<p>20. Smit PM, Veldhius S, Mulder JW, et al. Influenza vaccination and hemostasis: no sustainable procoagulant effects from 2009 H1N1 influenza vaccine in healthy healthcare workers. <i>J Thromb Haemost</i>. 2011;9(8):1659-1661. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21696536\">[PubMed 21696536]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8159":"<p><b>Title</b> Oxytocic Agents / Carboprost Tromethamine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Carboprost Tromethamine may enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of carboprost in combination with other oxytocic agents.</p>\n<div>\n <p><b>Oxytocic Agents Interacting Members</b> Carbetocin, Carboprost Tromethamine, Dinoprostone, Oxytocin</p>\n</div> \n<p><b>Discussion</b> Carboprost U.S. prescribing information warns that its use in combination with other oxytocic agents is not recommended, due to the theoretical potential for it to augment oxytocic effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hemabate (carboprost). New York, NY: Pfizer Inc, December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8160":"<p><b>Title</b> Cyproheptadine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of cyproheptadine in combination with monoamine oxidase inhibitors. Cyproheptadine U.S. prescribing information lists this combination as contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Cyproheptadine U.S. prescribing information lists its use in combination with monoamine oxidase inhibitors (MAOIs) as contraindicated, on the basis that MAO inhibition could increase or prolong cyproheptadine anticholinergic effects.<sup>1</sup> Published data describing these effects are lacking. However, several additional published case reports describe possible antagonism of serotonergic effects of monoamine oxidase inhibitors (linezolid, methylene blue, moclobemide, phenelzine, tranylcypromine) with concomitant or proximate use of cyproheptadine.<sup>2,3,4,5,6,7,8</sup> Both clinically beneficial effects (e.g., reversal of toxicity) and detrimental effects (e.g., reversal of antidepressant effects) have been described. One final published case report describes a patient who developed irritability, visual hallucinations and paranoia following 2 months of combined use of cyproheptadine and phenlzine,<sup>9</sup> although any connection of these features to an interaction between cyproheptadine and phenelzine is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cyproheptadine. Sellersville, PA: Teva Pharmaceuticals USA, 3/2009.</p>\n<p>2. Gupta V, Karnik ND, Deshpande R, Patil MA. Linezolid-induced serotonin syndrome. <i>BMJ Case Rep</i>. 2013 Mar 18. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23513014\">[PubMed 23513014]</a></p>\n<p>3. van Diepen S, Sobey A, Lewanczuk R, et al. A case of acute respiratory distress syndrome responsive to methylene blue during a carcinoid crisis. <i>Can J Anaesth</i>. 2013;60(11):1085-1088. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24037749\">[PubMed 24037749]</a></p>\n<p>4. Steinberg M, Morin AK. Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. <i>Am J Health Syst Pharm</i>. 2007;64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>5. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. <i>Pharmacotherapy</i>. 2006;26(2):269-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>6. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. <i>J Emerg Med</i>. 1998;16(4):615-619. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9696181\">[PubMed 9696181]</a></p>\n<p>7. Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. <i>J Clin Psychopharmacol</i>. 1993;13(5):312-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8227489\">[PubMed 8227489]</a></p>\n<p>8. Zubieta JK, Demitrack MA. Depression after cyproheptadine: MAO treatment. <i>Biol Psychiatry</i>. 1992;31(11):1177-1178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1525285\">[PubMed 1525285]</a></p>\n<p>9. Kahn DA. Possible toxic interaction between cyproheptadine and phenelzine. <i>Am J Psychiatry</i>. 1987;144(9):1242-1243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3631331\">[PubMed 3631331]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8161":"<p><b>Title</b> Alcohol (Ethyl) / Chloramphenicol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Caution patients about the potential for a disulfiram-like reaction (e.g., flushing, nausea, headache, vomiting, chest pain, vertigo, sweating, thirst, blurred vision, weakness, confusion, and/or hypotension) with alcohol ingestion while they are receiving chloramphenicol. To minimize the risk for any such reaction patients should discontinue alcohol consumption at least 48 hours before and after chloramphenicol administration.</p> \n<p><b>Discussion</b> Chloramphenicol has historically been listed as a medication that can elicit disulfiram-like reactions when combined with alcohol.<sup>1</sup> One study in rats showed that chloramphenicol produced a 30% inhibition of low-Km aldehyde dehydrogenase (ALDH) in the liver and 40% inhibition in the brain, similar to the effects of disulfiram.<sup>2</sup> An additional rat study showed that chloramphenicol inhibited ALDH2, enhanced brain serotonin, and significantly increased blood acetaldehyde levels when ethanol was co-administered, suggesting that serotonin could also contribute to the disulfiram-like reaction.<sup>3</sup><br><br>The proposed mechanism of action involves the build-up of acetaldehyde, a metabolite of ethanol, due to inhibition of aldehyde dehydrogenase. High levels of acetaldehyde can cause signs and symptoms associated with a disulfiram-like reactions, such as flushing, nausea, headache, vomiting, chest pain, vertigo, sweating, thirst, blurred vision, weakness, confusion, and hypotension.<sup>4</sup> An alternative proposed mechanism is the increase of serotonin triggered by medications. Clinical presentation of serotonin syndrome is widely variable and symptoms can mimic disulfiram-like reactions; therefore, theoretically, agents that increase serotonin in the brain can lead to a hyperserotonergic condition and can contribute symptoms of a disulfiram-like reaction.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Weathermon R, Crabb D. Alcohol and medication interactions. <i>Alcohol Res Health</i>. 1999;23(1):40-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10890797\">[PubMed 10890797]</a></p>\n<p>2. Vasilious V, Malamas M, Marselos M. The mechanism of alcohol intolerance produced by various therapeutic agents. <i>Acta Pharmcol Toxicol (Copenh)</i>. 1986;58(5):305-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2943133\">[PubMed 2943133]</a></p>\n<p>3. Karamanakos PN, Pappas P, Boumba VA, et al. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. <i>Int J Toxicol</i>. 2007;26(5):423-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17963129\">[PubMed 17963129]</a></p>\n<p>4. Barth KS, Malcolm RJ. Disulfiram: and old therapeutic with new applications. <i>CNS Neurol Disord Drug Targets</i>. 2010;9(1):5-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20201810\">[PubMed 20201810]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8162":"<p><b>Title</b> Alcohol (Ethyl) / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid alcohol ingestion while taking ketoconazole. The prescribing information for ketoconazole warns against concurrent use due to both a potential increase in the risk for hepatotoxicity and for the possibility of a disulfiram-like reaction.</p> \n<p><b>Discussion</b> Ketoconazole prescribing information notes that rare cases of a ketoconazole/alcohol interaction resulting in a disulfiram-like reaction have been reported.<sup>1,2</sup> The reactions were reportedly characterized by flushing, rash, peripheral edema, nausea, and headache that resolved within hours. Additionally, two separate case reports describing patients who experienced an intolerance to alcohol while taking oral ketoconazole 200 mg daily have been published.<sup>3,4</sup> The exact mechanism for this reported interaction is uncertain.<br><br>In addition, the ketoconazole prescribing information recommends that patients not consume alcohol while taking ketoconazole.<sup>1,2</sup> This warning appears to be largely due to the potential for both ketoconazole and alcohol to cause hepatic toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nizoral (ketoconazole). Titusville, NJ: Janssen Pharmaceuticals, Inc., 07/2013.</p>\n<p>2. Prescribing information. Ketoconazole. Sellersville, PA: Teva Pharmaceuticals USA, April 1998.</p>\n<p>3. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis--a prospective study of 12 cases. <i>Am J Gastroenterol</i>. 1983;78(5):261-264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6303114\">[PubMed 6303114]</a></p>\n<p>4. Meyboom RH, Pater BW. [Hypersensitivity to alcoholic beverages during treatment with ketoconazole]. <i>Ned Tijdschr Geneeskd</i>. 1989;133(29):1463-1464 (article in Dutch). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2797244\">[PubMed 2797244]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8163":"<p><b>Title</b> Carbocisteine / Ketoconazole (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, ketoconazole may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid alcohol ingestion while taking ketoconazole. The prescribing information for ketoconazole warns against concurrent use due to both a potential increase in the risk for hepatotoxicity and for the possibility of a disulfiram-like reaction. Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a disulfiram-like reaction (i.e., flushing, nausea, etc.) with ketoconazole in some patients. Monitor for flushing and changes in blood pressure and/or heart rate if an alcohol-containing product is administered to patients receiving ketoconazole. Solid oral dosage forms of carbocisteine products are not expected to share this interaction.</p> \n<p><b>Discussion</b> Ketoconazole prescribing information notes that rare cases of a ketoconazole/alcohol interaction resulting in a disulfiram-like reaction have been reported.<sup>1,2</sup> The reactions were reportedly characterized by flushing, rash, peripheral edema, nausea, and headache that resolved within hours. Additionally, two separate case reports describing patients who experienced an intolerance to alcohol while taking oral ketoconazole 200 mg daily have been published.<sup>3,4</sup> The exact mechanism for this reported interaction is uncertain.<br><br>In addition, the ketoconazole prescribing information recommends that patients not consume alcohol while taking ketoconazole.<sup>1,2</sup> This warning appears to be largely due to the potential for both ketoconazole and alcohol to cause hepatic toxicity.<br><br>Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Nizoral (ketoconazole). Titusville, NJ: Janssen Pharmaceuticals, Inc., 07/2013.</p>\n<p>2. Prescribing information. Ketoconazole. Sellersville, PA: Teva Pharmaceuticals USA, April 1998.</p>\n<p>3. Fazio RA, Wickremesinghe PC, Arsura EL. Ketoconazole treatment of Candida esophagitis--a prospective study of 12 cases. <i>Am J Gastroenterol</i>. 1983;78(5):261-264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6303114\">[PubMed 6303114]</a></p>\n<p>4. Meyboom RH, Pater BW. [Hypersensitivity to alcoholic beverages during treatment with ketoconazole]. <i>Ned Tijdschr Geneeskd</i>. 1989;133(29):1463-1464 (article in Dutch). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2797244\">[PubMed 2797244]</a></p>\n<p>5. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>6. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>7. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>8. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8164":"<p><b>Title</b> Carbocisteine / Chloramphenicol (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, chloramphenicol may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a disulfiram-like reaction (i.e., flushing, nausea, etc.) with chloramphenicol in some patients. Monitor for flushing and changes in blood pressure and/or heart rate if an alcohol-containing product is administered to patients receiving chloramphenicol. Solid oral dosage forms of carbocisteine products are not expected to share this interaction.</p> \n<p><b>Discussion</b> Chloramphenicol has historically been listed as a medication that can elicit disulfiram-like reactions when combined with alcohol.<sup>1</sup> One study in rats showed that chloramphenicol produced a 30% inhibition of low-Km aldehyde dehydrogenase (ALDH) in the liver and 40% inhibition in the brain, similar to the effects of disulfiram.<sup>2</sup> An additional rat study showed that chloramphenicol inhibited ALDH2, enhanced brain serotonin, and significantly increased blood acetaldehyde levels when ethanol was co-administered, suggesting that serotonin could also contribute to the disulfiram-like reaction.<sup>3</sup><br><br>The proposed mechanism of action involves the build-up of acetaldehyde, a metabolite of ethanol, due to inhibition of aldehyde dehydrogenase. High levels of acetaldehyde can cause signs and symptoms associated with a disulfiram-like reactions, such as flushing, nausea, headache, vomiting, chest pain, vertigo, sweating, thirst, blurred vision, weakness, confusion, and hypotension.<sup>4</sup> An alternative proposed mechanism is the increase of serotonin triggered by medications. Clinical presentation of serotonin syndrome is widely variable and symptoms can mimic disulfiram-like reactions; therefore, theoretically, agents that increase serotonin in the brain can lead to a hyperserotonergic condition and can contribute symptoms of a disulfiram-like reaction.<sup>3</sup><br><br>Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Weathermon R, Crabb D. Alcohol and medication interactions. <i>Alcohol Res Health</i>. 1999;23(1):40-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10890797\">[PubMed 10890797]</a></p>\n<p>2. Vasilious V, Malamas M, Marselos M. The mechanism of alcohol intolerance produced by various therapeutic agents. <i>Acta Pharmcol Toxicol (Copenh)</i>. 1986;58(5):305-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2943133\">[PubMed 2943133]</a></p>\n<p>3. Karamanakos PN, Pappas P, Boumba VA, et al. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. <i>Int J Toxicol</i>. 2007;26(5):423-432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17963129\">[PubMed 17963129]</a></p>\n<p>4. Barth KS, Malcolm RJ. Disulfiram: and old therapeutic with new applications. <i>CNS Neurol Disord Drug Targets</i>. 2010;9(1):5-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20201810\">[PubMed 20201810]</a></p>\n<p>5. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>6. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>7. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>8. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8165":"<p><b>Title</b> Carbocisteine / Griseofulvin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Griseofulvin may enhance the adverse/toxic effect of Carbocisteine. Specifically, griseofulvin may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a disulfiram-like reaction (i.e., flushing, nausea, etc.) with griseofulvin in some patients. Monitor for flushing and changes in blood pressure and/or heart rate if an alcohol-containing product is administered to patients receiving griseofulvin. Solid oral dosage forms of carbocisteine products are not expected to share this interaction.</p> \n<p><b>Discussion</b> Coadministration of griseofulvin and alcohol has resulted in a single case of disulfiram-like reaction.<sup>1</sup> Other cases of flushing and tachycardia associated with coadministration of these products have been reported.<sup>2</sup> The mechanism is unclear. Griseofulvin may inhibit aldehyde dehydrogenase, like disulfiram, and thus reduce the metabolism of acetaldehyde (the metabolite of alcohol).<br><br>Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fett DL, Vukov LF. An unusual case of severe griseofulvin-alcohol interaction. <i>Ann Emerg Med</i>. 1994;24:95-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8010556\">[PubMed 8010556]</a></p>\n<p>2. Prescribing information. Gris-PEG (griseofulvin). Farmingdale, NY: Pedinol Pharmacal Inc., 10/10.</p>\n<p>3. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>4. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>5. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>6. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8166":"<p><b>Title</b> Carbocisteine / Procarbazine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction applies specifically to liquid formulations of carbocisteine-containing products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Procarbazine may enhance the adverse/toxic effect of Carbocisteine. Specifically, procarbazine may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Liquid formulations of carbocisteine-containing products contain alcohol, which may cause a disulfiram-like reaction (i.e., flushing, nausea, etc.) with procarbazine in some patients. Monitor for flushing and changes in blood pressure and/or heart rate if an alcohol-containing product is administered to patients receiving procarbazine. Solid oral dosage forms of carbocisteine products are not expected to share this interaction.</p> \n<p><b>Discussion</b> Case reports of patients receiving procarbazine describe facial flushing after consuming alcoholic beverages.<sup>1,2</sup> The mechanism is unclear. Procarbazine may inhibit aldehyde dehydrogenase, like disulfiram, and thus reduce the metabolism of acetaldehyde (the metabolite of alcohol).<br><br>Liquid formulations of carbocisteine-containing products contain 0.2 g of alcohol per 15 mL dose.<sup>3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mathe' G, Berumen L, Schweisguth O, et al. Methyl-hydrazine in the treatment of Hodgkin's disease and various forms of haematosarcoma and leukaemia. <i>Lancet</i>. 1963;2:1077-1080. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14063416\">[PubMed 14063416]</a></p>\n<p>2. Todd IDH. Natulan in the management of late Hodgkin's disease, other lymphoreticular neoplasms, and malignant melanoma. <i>BMJ</i>. 1965;1:626-631. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14245179\">[PubMed 14245179]</a></p>\n<p>3. Summary of product characteristics. Rhinathiol (carbocisteine). Paris, France: Sanofi-Aventis France, 01/2012.</p>\n<p>4. Summary of product characteristics (Singapore). Rhinathiol (carbocisteine). Colomiers, France: Unither Liquid Manufacturing, March 2012.</p>\n<p>5. Summary of product characteristics. Mucodyne (carbocisteine). Guildford, Surrey, United Kingdom: Aventis Pharma Limited, 04/2013.</p>\n<p>6. Summary of product characteristics. Rhinathiol Promethazine (carbocisteine and promethazine). Paris, France: Sanofi-Aventis France, 06/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8168":"<p><b>Title</b> Dabrafenib / Trametinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trametinib may enhance the adverse/toxic effect of Dabrafenib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> This combination should be used with caution and with close monitoring for the appearance of possible treatment-related toxicities. Patients should be advised to immediately seek treatment for any toxicity that may be treatment-related. The prescribing information for both agents provide specific recommendations for management of such toxicities.</p> \n<p><b>Discussion</b> According to the prescribing information for both dabrafenib and trametinib, concurrent use of these agents may be associated with an increased risk for hemorrhage, venous thromboembolism, serious febrile reactions, and other toxicities.<sup>1,2</sup> Most of these warnings appear to be based on a clinical trial in which patients with metastatic melanoma received either combination therapy (dabrafenib 150 mg twice/day plus either trametinib 1 mg daily or trametinib 2 mg daily) or dabrafenib alone.<sup>3</sup> Of subjects receiving the combination, 69-71% experienced fever compared to 26% of those receiving dabrafenib monotherapy.<sup>1,2,3</sup> Combination therapy was also associated with more cases of serious fever or fever with hypotension, chills, or rigors (25% vs. 2%). An increased incidence and severity of hemorrhagic events (16% vs. 2%), including more major hemorrhagic events (5% vs. 0%), and an increased number of thromboembolic events (7% vs. 0%) were also noted with combination therapy as compared to dabrafenib monotherapy, though these events were not detailed in the study publication, and are just summarized in the prescribing information.<sup>1,2,3</sup><br><br>The specific mechanism(s) for this apparent increased toxicity with concurrent use is(are) unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Mekinist (trametinib). Research Triangle Park, NC: GlaxoSmithKline, 01/2014.</p>\n<p>2. Prescribing information. Tafinlar (dabrafenib). Research Triangle Park, NC: GlaxoSmithKline, 01/2014.</p>\n<p>3. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. <i>N Engl J Med</i>. 2012;367(18):1694-1703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23020132\">[PubMed 23020132]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8169":"<p><b>Title</b> Rosiglitazone / Cholestyramine Resin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cholestyramine Resin may decrease the serum concentration of Rosiglitazone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer rosiglitazone at least 2 hours prior to cholestyramine in order to minimize the likelihood of an interaction. Monitor for evidence of reduced rosiglitazone effectiveness if this combination is used. The bile acid sequestrant colesevelam reportedly does not significantly interact with rosiglitazone.</p> \n<p><b>Discussion</b> A study in rats found that cholestyramine administration was associated with a dose-dependent decrease in the AUC and maximum serum concentration (Cmax) of oral rosiglitazone administered 30 minutes after cholestyramine.<sup>1</sup> The overall bioavailability of rosiglitazone was reduced by 20-72% when given after cholestyramine. Administration of rosiglitazone either 2 hours or 4 hours prior to cholestyramine was associated with no significant change in rosiglitazone AUC, but administration 1 hour prior to cholestyramine was associated with a reduction in the rosiglitazone AUC. A separate in vitro study using several concentrations of both cholestyramine and rosiglitazone, and at different pH values, found that cholestyramine binding was 50-72% at pH 2, 74-89% at pH 4, and 97-100% at pH 7.<sup>1</sup><br><br>Data with the bile acid sequestrant colesevelam suggest that this interaction may not extend to all other bile acid sequestrants, as colesevelam reportedly does not interact with either rosiglitazone or pioglitazone (another thiazolidinedione).<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Muzeeb S, Venkatesh P, Mullangi R, Srinivas NR. Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. <i>Xenobiotica</i>. 2006;36(9):838-856. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16971347\">[PubMed 16971347]</a></p>\n<p>2. Brown KS, Armstrong IC, Wang A, et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. <i>J Clin Pharmacol</i>. 2010;50(5):554-565. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19789374\">[PubMed 19789374]</a></p>\n<p>3. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc., 01/2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8170":"<p><b>Title</b> Indium 111 Capromab Pendetide / Luteinizing Hormone-Releasing Hormone Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for altered imaging performance, indium 111 capromab pendetide is not recommended for use in patients receiving luteinizing hormone-releasing hormone analogs.</p>\n<div>\n <p><b>Luteinizing Hormone-Releasing Hormone Analogs Interacting Members</b> Buserelin, Goserelin, Histrelin, Leuprolide, Nafarelin, Triptorelin</p>\n</div> \n<p><b>Discussion</b> Capromab pendetide U.S. prescribing information states that use of indium 111 capromab pendetide cannot be recommended in patients receiving surgical and/or medical androgen suppression treatment.<sup>1</sup> The antibody portion of this agent targets prostate specific membrane antigen, which preliminary data suggest may be up-regulated during androgen suppression.<sup>1</sup> Agents commonly used in medical androgen suppression regimens include luteinizing hormone-releasing hormone analogs, antigonadotropic agents, estrogens, corticosteroids, some progestins (e.g., cyproterone), abiraterone acetate, ketoconazole, and several others.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. ProstaScint (capromab pendetide). Langhorne, PA: EUSA Pharma (USA), Inc., December 2010.</p>\n<p>2. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. <i>J Natl Compr Canc Netw</i>. 2013;11(12):1471-1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24335682\">[PubMed 24335682]</a></p>\n<p>3. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. <i>BJU Int</i>. 2012;110 (suppl 1):23-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23046037\">[PubMed 23046037]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8171":"<p><b>Title</b> Indium 111 Capromab Pendetide / Antigonadotropic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antigonadotropic Agents may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for altered imaging performance, indium 111 capromab pendetide is not recommended for use in patients receiving antigonadotropic agents.</p>\n<div>\n <p><b>Antigonadotropic Agents Interacting Members</b> Cetrorelix, Degarelix, Ganirelix</p>\n</div> \n<p><b>Discussion</b> Capromab pendetide U.S. prescribing information states that use of indium 111 capromab pendetide cannot be recommended in patients receiving surgical and/or medical androgen suppression treatment.<sup>1</sup> The antibody portion of this agent targets prostate specific membrane antigen, which preliminary data suggest may be up-regulated during androgen suppression.<sup>1</sup> Agents commonly used in medical androgen suppression regimens include luteinizing hormone-releasing hormone analogs, antigonadotropic agents, estrogens, corticosteroids, some progestins (e.g., cyproterone), abiraterone acetate, ketoconazole, and several others.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. ProstaScint (capromab pendetide). Langhorne, PA: EUSA Pharma (USA), Inc., December 2010.</p>\n<p>2. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. <i>J Natl Compr Canc Netw</i>. 2013;11(12):1471-1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24335682\">[PubMed 24335682]</a></p>\n<p>3. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. <i>BJU Int</i>. 2012;110 (suppl 1):23-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23046037\">[PubMed 23046037]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8172":"<p><b>Title</b> Indium 111 Capromab Pendetide / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for altered imaging performance, indium 111 capromab pendetide is not recommended for use in patients receiving estrogen derivatives.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> Capromab pendetide U.S. prescribing information states that use of indium 111 capromab pendetide cannot be recommended in patients receiving surgical and/or medical androgen suppression treatment.<sup>1</sup> The antibody portion of this agent targets prostate specific membrane antigen, which preliminary data suggest may be up-regulated during androgen suppression.<sup>1</sup> Agents commonly used in medical androgen suppression regimens include luteinizing hormone-releasing hormone analogs, antigonadotropic agents, estrogens, corticosteroids, some progestins (e.g., cyproterone), abiraterone acetate, ketoconazole, and several others.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. ProstaScint (capromab pendetide). Langhorne, PA: EUSA Pharma (USA), Inc., December 2010.</p>\n<p>2. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. <i>J Natl Compr Canc Netw</i>. 2013;11(12):1471-1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24335682\">[PubMed 24335682]</a></p>\n<p>3. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. <i>BJU Int</i>. 2012;110 (suppl 1):23-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23046037\">[PubMed 23046037]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8173":"<p><b>Title</b> Indium 111 Capromab Pendetide / Antiandrogens</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for altered imaging performance, indium 111 capromab pendetide is not recommended for use in patients receiving antiandrogens.</p>\n<div>\n <p><b>Antiandrogens Interacting Members</b> Abiraterone Acetate, Apalutamide, Bicalutamide, Cyproterone, Enzalutamide, Flutamide, Ketoconazole (Systemic), MedroxyPROGESTERone, Megestrol, Nilutamide</p>\n</div> \n<p><b>Discussion</b> Capromab pendetide U.S. prescribing information states that use of indium 111 capromab pendetide cannot be recommended in patients receiving surgical and/or medical androgen suppression treatment.<sup>1</sup> The antibody portion of this agent targets prostate specific membrane antigen, which preliminary data suggest may be up-regulated during androgen suppression.<sup>1</sup> Agents commonly used in medical androgen suppression regimens include luteinizing hormone-releasing hormone analogs, antigonadotropic agents, estrogens, corticosteroids, some progestins (e.g., cyproterone), abiraterone acetate, ketoconazole, and several others.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. ProstaScint (capromab pendetide). Langhorne, PA: EUSA Pharma (USA), Inc., December 2010.</p>\n<p>2. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. <i>J Natl Compr Canc Netw</i>. 2013;11(12):1471-1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24335682\">[PubMed 24335682]</a></p>\n<p>3. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. <i>BJU Int</i>. 2012;110 (suppl 1):23-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23046037\">[PubMed 23046037]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8174":"<p><b>Title</b> Indium 111 Capromab Pendetide / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for altered imaging performance, indium 111 capromab pendetide is not recommended for use in patients receiving androgen suppression regimens containing systemic corticosteroids.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Capromab pendetide U.S. prescribing information states that use of indium 111 capromab pendetide cannot be recommended in patients receiving surgical and/or medical androgen suppression treatment.<sup>1</sup> The antibody portion of this agent targets prostate specific membrane antigen, which preliminary data suggest may be up-regulated during androgen suppression.<sup>1</sup> Agents commonly used in medical androgen suppression regimens include luteinizing hormone-releasing hormone analogs, antigonadotropic agents, estrogens, corticosteroids, some progestins (e.g., cyproterone), abiraterone acetate, ketoconazole, and several others.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. ProstaScint (capromab pendetide). Langhorne, PA: EUSA Pharma (USA), Inc., December 2010.</p>\n<p>2. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 1.2014. <i>J Natl Compr Canc Netw</i>. 2013;11(12):1471-1479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24335682\">[PubMed 24335682]</a></p>\n<p>3. Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. <i>BJU Int</i>. 2012;110 (suppl 1):23-29. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23046037\">[PubMed 23046037]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8175":"<p><b>Title</b> Stiripentol / CloBAZam</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Phenotype</b>: This magnitude and significance of this interaction may vary according to CYP2C19 phenotype, with extensive and intermediate metabolizers more likely to experience a change in clobazam concentrations with the combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CloBAZam may increase the serum concentration of Stiripentol. Stiripentol may increase the serum concentration of CloBAZam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Stiripentol is indicated for use with clobazam and valproic acid, but clobazam dose reduction may be necessary when used as part of this combination. Monitor patient response to therapy closely following initiation of the combination, and adjust clobazam doses according to clinical response. Clobazam dose reductions of up to 25% per week may be needed.</p> \n<p><b>Discussion</b> Concentrations of clobazam and norclobazam were approximately 2- to 3-fold and 5-fold higher, respectively, with concurrent stiripentol according to the official product monograph and other published data.<sup>1,2</sup> An in vitro study also found that stiripentol inhibited both clobazam N-demethylation to norclobazam (NCLB) and the 4'-hydroxylation of NCLB.<sup>3</sup> Data from patients with known CYP2C19 genotypes suggest that patients with at least one functional copy of the gene encoding CYP2C19 are sensitive to this interaction, while those carrying two loss-of-function alleles (i.e., CYP2C19 “poor metabolizers”) did not display any significant change in clobazam concentrations with concurrent stiripentol.<sup>2</sup><br><br>Additionally, stiripentol concentrations were increased by an average of 25% with concurrent clobazam according to an analysis of 220 stiripentol concentrations from 75 patients.<sup>4</sup> <br><br>The mechanisms for this apparent dual interaction appear to be both stiripentol inhibition of clobazam metabolism (primarily via CYP2C19 inhibition, with some possible role of CYP3A4 inhibition) and clobazam inhibition of stiripentol metabolism. The specifics of how clobazam alters stiripentol elimination are uncertain, though, as clobazam is not recognized as a significant inhibitor of the enzymes that are thought to primarily contribute to stiripentol metabolism (i.e., CYP1A2, CYP2C19, or CYP3A).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p>2. Yamamoto Y, Takahashi Y, Imai K, et al. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. <i>Ther Drug Monit</i>. 2013;35(3):305-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23666564\">[PubMed 23666564]</a></p>\n<p>3. Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. <i>Drug Metab Dispos</i>. 2006;34(4):608-611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16415114\">[PubMed 16415114]</a></p>\n<p>4. May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. <i>Ther Drug Monit</i>. 2012;34(4):390-397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22743350\">[PubMed 22743350]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8176":"<p><b>Title</b> Alcohol (Ethyl) / Stiripentol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Stiripentol may enhance the sedative effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Advise patients to avoid ingestion of alcohol and/or alcohol-containing products while taking stiripentol. Enhanced sedative effects (both magnitude and duration) are possible with the combination.</p> \n<p><b>Discussion</b> According to the offical stiripentol product monograph, animal data showed that stiripentol enhanced the sensitivity to alcohol-related sedative effects and increased the duration of sedation.<sup>1</sup> Though in vivo data regarding use of this combination are not available, the product monograph recommends that patients avoid the use of alcohol or any alcohol-containing products while being treated with stiripentol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8177":"<p><b>Title</b> Stiripentol / PHENobarbital</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> PHENobarbital may decrease the serum concentration of Stiripentol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> According to the stiripentol product monograph, phenobarbital should not be used with stiripentol in the management of Dravet Syndrome.</p> \n<p><b>Discussion</b> Concurrent use of phenytoin or phenobarbital with stiripentol was associated with an average 63% reduction in serum stiripentol concentrations in a subgroup of 7 patients who were part of a larger retrospective evaluation of 220 stiripentol concentrations from 75 patients.<sup>1</sup> A study in mice similarly reported that phenobarbital administration decreased brain stiripentol concentrations, and that stiripentol increased brain phenobarbital concentrations.<sup>2</sup> According to the stiripentol product monograph, phenobarbital should not be used with stiripentol in the management of Dravet Syndrome.<sup>3</sup><br><br>The specific mechanism for this interaction is likely phenobarbital induction of the enzymes responsible for stiripentol metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. <i>Ther Drug Monit</i>. 2012;34(4):390-397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22743350\">[PubMed 22743350]</a></p>\n<p>2. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ. Characterization of the anticonvulsant, behavioral and pharmacokinetic interaction profiles of stiripentol in combination with clonazepam, ethosuximide, phenobarbital, and valproate using isobolographic analysis. <i>Epilepsia</i>. 2006;47(11):1841-1854. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17116023\">[PubMed 17116023]</a></p>\n<p>3. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8178":"<p><b>Title</b> Phenytoin / Stiripentol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Stiripentol may decrease the serum concentration of Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> According to the stiripentol product monograph, phenytoin should not be used with stiripentol in the management of Dravet Syndrome.</p> \n<p><b>Discussion</b> Concurrent use of phenytoin or phenobarbital with stiripentol was associated with an average 63% reduction in serum stiripentol concentrations in a subgroup of 7 patients who were part of a larger retrospective evaluation of 220 stiripentol concentrations from 75 patients.<sup>1</sup> According to the stiripentol product monograph, phenytoin should not be used with stiripentol in the management of Dravet Syndrome.<sup>2</sup><br><br>The specific mechanism for this interaction is likely phenytoin induction of the enzymes responsible for stiripentol metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. <i>Ther Drug Monit</i>. 2012;34(4):390-397. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22743350\">[PubMed 22743350]</a></p>\n<p>2. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8179":"<p><b>Title</b> CarBAMazepine / Stiripentol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Stiripentol may increase the serum concentration of CarBAMazepine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> According to the stiripentol product monograph,carbamazepine should not be used with stiripentol in the management of Dravet Syndrome.</p> \n<p><b>Discussion</b> Concurrent stiripentol was associated with a significant 45-65% reduction in the carbamazepine epoxide/carbamazepine ratio according to several studies in children with epilepsy who were being treated with carbamazepine.<sup>1,2,3</sup> This decrease was correlated with stiripentol concentrations.<sup>2</sup> One study also noted that the carbamazepine clearance decreased by an average of 50% and that this interaction demonstrated a gradual onset over 7-10 days.<sup>3</sup> The authors of two of these studies recommended gradual carbamazepine dose reductions of possibly more than 50% in order to minimize the consequences of this interaction;<sup>2,3</sup> however, the stiripentol product monograph states that carbamazepine should not be used with stiripentol in the management of Dravet Syndrome.<sup>4</sup><br><br>The mechanism of this interaction appears to be stiripentol inhibition of the metabolism of carbamazepine to its 10,11-epoxide via inhibition of CYP2C8 and/or CYP3A4.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cazali N, Tran A, Treluyer JM, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. <i>Br J Clin Pharmacol</i>. 2003;56(5):526-536. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14651727\">[PubMed 14651727]</a></p>\n<p>2. Tran A, Vauzelle-Kervroedan F, Rey E, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. <i>Eur J Clin Pharmacol</i>. 1996;50(6):497-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8858278\">[PubMed 8858278]</a></p>\n<p>3. Kerr BM, Martinez-Lage JM, Viteri C, Tor J, Eddy AC, Levy RH. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. <i>Epilepsia</i>. 1991;32(2):267-274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2004631\">[PubMed 2004631]</a></p>\n<p>4. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8180":"<p><b>Title</b> Theophylline / Stiripentol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Stiripentol may increase the serum concentration of Theophylline. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> According to the stiripentol product monograph, patients taking stiripentol should not consume theophylline due to the risk for increased theophylline concentrations and effects.</p> \n<p><b>Discussion</b> The stiripentol product monograph warns that stiripentol may inhibit the metabolism of theophylline, though there are no specific data presented such concurrent use.<sup>1</sup> Since such an interaction can not be excluded, however, patients taking stiripentol are cautioned not to take theophylline.<br><br>The specific mechanism for this possible interaction is most likely stiripentol inhibition of the CYP1A2-mediated metabolism of theophylline, as stiripentol is characterized as an inhibitor of CYP1A2.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p>2. Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. <i>Clin Pharmacol Ther</i>. 1997;62(5):490-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9390105\">[PubMed 9390105]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8182":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Stiripentol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Stiripentol may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The stiripentol product monograph cautions that concurrent use of stiripentol with CYP3A4 substrates may result in increased concentrations and effects (including an increased risk of adverse effects) of the CYP3A4 substrates, necessitating caution with any concurrent use. Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> Several in vitro studies have concluded that stiripentol was an inhibitor of CYP3A4,<sup>1,2,3</sup> with clinical observations of interactions with clobazam and carbamazepine, both of which appear to be at least partially metabolized by CYP3A, further supporting a likely clinically significant inhibition of CYP3A4.<sup>1,2</sup> Based on the potential for interactions with drugs that are metabolized by CYP3A4, the stiripentol product monograph cautions that concurrent use of stiripentol with CYP3A4 substrates may result in increased concentrations and effects (including an increased risk of adverse effects) of the CYP3A4 substrates, necessitating caution with any concurrent use.<sup>4</sup> Concurrent use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. <i>Drug Metab Dispos</i>. 2006;34(4):608-611. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16415114\">[PubMed 16415114]</a></p>\n<p>2. Cazali N, Tran A, Treluyer JM, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. <i>Br J Clin Pharmacol</i>. 2003;56(5):526-536. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14651727\">[PubMed 14651727]</a></p>\n<p>3. Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. <i>Clin Pharmacol Ther</i>. 1997;62(5):490-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9390105\">[PubMed 9390105]</a></p>\n<p>4. Product monograph. Diacomit (stiripentol). Dundas, Ontario, Canada: C.R.I., December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8196":"<p><b>Title</b> Thalidomide / Estrogen Derivatives (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives (Contraceptive) may enhance the thrombogenic effect of Thalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients using this combination closely for signs and symptoms of thromboembolism such as swelling, redness, warmth, or pain in the legs, dyspnea, tachypnea, hemoptysis, or chest pain. Advise patients of potential risks and encourage prompt reporting of any thromboembolism signs or symptoms.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Thalidomide prescribing information warns of a possible increase in the risk for thromboembolism in patients receiving concomitant hormonal contraceptives, though specific data regarding the actual risks with the combination are lacking.<sup>1</sup> The use of thalidomide itself is associated with a significant risk for thromboembolism; as described in the prescribing information, 22% of those treated with thalidomide plus dexamethasone experienced thromboembolism versus 5% of those treated with dexamethasone alone in a study of patients with multiple myeloma.<sup>1</sup><br><br>Available evidence suggests there is not a pharmacokinetic interaction between these agents. One study in ten healthy premenopausal female volunteers and another study in ten surgically sterilized women each showed no effect on either thalidomide or ethinyl estradiol/norethindrone concentrations when subjects were co-administered thalidomide (200 mg/day, for 21 days) and a single dose of ethinyl estradiol/norethindrone (0.07 mg/2 mg).<sup>2,3</sup> Only mild-moderate adverse effects were noted, none of which involved thrombosis.<br><br>The proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Thalidomid (thalidomide). Summit, NJ: Celgene Corporation, February 2013.</p>\n<p>2. Trapnell CB, Donahue SR, Collins JM, Flockhart DA, Thacker D, Abernethy DR. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. <i>Clin Pharmacol Ther</i>. 1998;64(6):597-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871424\">[PubMed 9871424]</a></p>\n<p>3. Scheffler MR, Colburn W, Kook KA, Thomas SD. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. <i>Clin Pharmacol Ther</i>. 1999;65(5):483-490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10340913\">[PubMed 10340913]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8197":"<p><b>Title</b> Thalidomide / Progestins (Contraceptive)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Progestins (Contraceptive) may enhance the thrombogenic effect of Thalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients using this combination extra closely for signs and symptoms of thromboembolism such as swelling, redness, warmth, or pain in the legs, dyspnea, tachypnea, hemoptysis, or chest pain. Advise patients of potential risks and encourage prompt reporting of any thromboembolism signs or symptoms.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Thalidomide prescribing information warns of a possible increase in the risk for thromboembolism in patients receiving concomitant hormonal contraceptives, though specific data regarding the actual risks with the combination are lacking.<sup>1</sup> The use of thalidomide itself is associated with a significant risk for thromboembolism; as described in the prescribing information, 22% of those treated with thalidomide plus dexamethasone experienced thromboembolism versus 5% of those treated with dexamethasone alone in a study of patients with multiple myeloma.<sup>1</sup><br><br>Available evidence suggests there is not a pharmacokinetic interaction between these agents. One study in ten healthy premenopausal female volunteers and another study in ten surgically sterilized women each showed no effect on either thalidomide or ethinyl estradiol/norethindrone concentrations when subjects were co-administered thalidomide (200 mg/day, for 21 days) and a single dose of ethinyl estradiol/norethindrone (0.07 mg/2 mg).<sup>2,3</sup> Only mild-moderate adverse effects were noted, none of which involved thrombosis.<br><br>The proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Thalidomid (thalidomide). Summit, NJ: Celgene Corporation, February 2013.</p>\n<p>2. Trapnell CB, Donahue SR, Collins JM, Flockhart DA, Thacker D, Abernethy DR. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. <i>Clin Pharmacol Ther</i>. 1998;64(6):597-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9871424\">[PubMed 9871424]</a></p>\n<p>3. Scheffler MR, Colburn W, Kook KA, Thomas SD. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. <i>Clin Pharmacol Ther</i>. 1999;65(5):483-490. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10340913\">[PubMed 10340913]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8198":"<p><b>Title</b> BuPROPion / Anti-Parkinson Agents (Dopamine Agonist)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients extra closely for evidence of CNS toxicities such as restlessness, agitation, tremor, ataxia, gait disturbance, vertigo, or dizziness with use of this combination. Advise patients about the potential for such adverse effects and advise them to promptly report any such effects.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine, Bromocriptine, Levodopa, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n</div> \n<p><b>Discussion</b> The bupropion prescribing information warns of a potential cumulative dopamine agonist effect and possible related toxicities when bupropion is used concomitantly with dopaminergic drugs.<sup>1</sup> According to the prescribing information, CNS toxicities such as restlessness, agitation, ataxia, gait disturbances, vertigo, and dizziness have been reported with concurrent use of the dopaminergic drugs levodopa or amantadine. Of note, several case reports have described successful administration of bupropion (150 mg/day) with other dopaminergic medications for treatment of dopamine agonist-mediated compulsive behaviors and depression.<sup>2,3,4</sup><br><br>The proposed mechanism of this potential interaction is an additive dopamine agonist effect with concomitant dopaminergic medications.</p> \n<p><b>Footnotes</b> </p>\n<p> 1. Prescribing Information. Wellbutrin (bupropion hydrochloride). Research Triangle Park, NC: GlaxoSmithKline, December 2013.</p>\n<p>2. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. <i>Ned Tijdschr Geneeskd</i>. 2000;144(45):2157-2159. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11086491\">[PubMed 11086491]</a> </p>\n<p>3. Benincasa Di, Pellicano C, Fanciulli A, Pontieri FE. Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson’s disease. <i>Mov Disord</i>. 2011;26(2):355-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21412840\">[PubMed 21412840]</a></p>\n<p>4. Zaluska M, Dyduch A. Bupropion in the treatment of depression in Parkinson’s Disease. <i>Int Psychogeriatr</i>. 2011;23(2):325-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20809995\">[PubMed 20809995]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8199":"<p><b>Title</b> Thalidomide / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Thalidomide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of medications with CNS depressant effects together with thalidomide should be avoided due to the risk for additive sedative effects.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Thalidomide prescribing information warns of potential additive sedative effect when thalidomide is used concomitantly with medications that cause CNS depression and states that use of such combinations should be avoided.<sup>1</sup> Thalidomide itself is associated with frequent drowsiness and somnolence.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Thalidomid (thalidomide). Summit, NJ: Celgene Corporation, February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}